PARG inhibitor

Abstract

Provided herein are crystalline forms of a PARG inhibitor having the formula of Compound 1. Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline forms of Compound 1, described herein.

Description

PARG INHIBITORCROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 63 / 584,035 filed September 20, 2023 and U.S. Provisional Application No. 63 / 605,189 filed December 01, 2023, the contents of each are incorporated by reference in their entirety for all purposes.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

[0002] NOT APPLICABLEREFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK

[0003] NOT APPLICABLEBACKGROUND

[0004] Cancer is caused by uncontrolled and unregulated cellular proliferation. The consequence of this often-rapid proliferation is a high level of oxidative stress within the tumor which damages DNA and leads to a much-increased mutation rate. Tumor cells therefore engage and rely heavily upon DNA damage repair mechanisms.

[0005] Single-strand breaks (SSBs) are the most common type of lesion arising in cells and PARG (Poly ADP-ribose glycohydrolase) together with PARP (poly ADP-ribose polymerase) is involved along with a number of other proteins in single strand break repair (SSBR) and another repair mechanism called base excision repair (BER).

[0006] One of the earliest events during single strand DNA repair is the binding of PARP (poly ADP-ribose polymerase) to the break and the rapid synthesis of poly ADP-ribose (PAR) on PARP itself. This molecular structure serves as a signal to recruit other DNA repair proteins, initially XRCC1, which will then repair the break (Mortusewicz, Fouquerel et al.2011). The signal initiated by these PAR chains is short-lived as they are rapidly degraded by the enzyme PARG. When PARP is bound to PAR, its catalytic activity is reduced andtherefore PARG activity helps to restore PARP to its catalytically active form (Curtin and Szabo 2013).

[0007] PARG is derived from a single gene with isoforms that reside in the nucleus, mitochondria and cytosol. Another known protein with glycohydrolase activity is ARH3 which is localized to the mitochondria (Mashimo, Kato et al. 2014). Although, known primarily for its direct role in DNA repair, PARG impacts PAR signaling in splicing, transcriptional and epigenetic pathways (Ji and Tulin 2009) (Le May, litis et al. 2012) (Dahl, Maturi et al. 2014) (Guastafierro, Catizone et al. 2013) (Caiafa, Guastafierro et al. 2009).

[0008] Cancer cells may become reliant upon a specific DNA repair pathway when other mechanisms of DNA repair are non-functional. Tumors carrying mutations in proteins involved in double strand break repair are often more sensitive to PARP inhibitors of SSBR. There is already some evidence that PARG depletion inhibits SSBR and reduces survival of BRCA2-deficient cells (Fathers, Drayton et al. 2012). However, other tumor mutations may give rise to deficiencies in double strand DNA repair mechanisms (so-called “BRCA-ness”) thereby sensitizing tumor cells to PARG inhibition.

[0009] PARG depletion has been studied in a number of murine and human model systems. Murine cells that are null or depleted for PARG display an increased sensitivity to experimental and clinical DNA damaging agents. However, as deficiency in PARG doesn’t sensitize to all agents (e.g. gemcitabine, camptothecin) this suggests a specificity for PARG function with certain pathways of DNA damage repair and chemo- and radiotherapies (Fujihara, Ogino et al. 2009) (Shirai, Fujimori et al. 2013) (Zhou, Feng et al. 2010) (Zhou, Feng et al. 2011).

[0010] In humans, PARG depletion sensitizes lung, cervical and pancreatic cancer cells to y- irradiation or experimental DNA damaging agents (e.g. hydrogen peroxide, Methylmethanesulfonate) (Ame, Fouquerel et al. 2009) (Nakadate, Kodera et al. 2013) (Shirai, Poetsch et al. 2013).

[0011] PARP inhibitors are currently undergoing multiple clinical trials where the concept of synthetic lethality or chemo-sensitization is being explored. Clinical resistance to PARP inhibitors has already been described (Drost and Jonkers 2014) (Barber, Sandhu et al. 2013) and therefore there is a requirement that alternative inhibitors targeting the DNA damage repair machinery are found.

[0012] Although current models show that PARG depletion leads to PARP-dependent effects on DNA repair, recent research has shown a mechanistic differentiation from PARP inhibition. Following a genotoxic stimulus depletion of PARG, in contrast to PARP depletion, leads to a drop in NAD levels. This leads to lung cancer cell death as a result of energy failure (Erdelyi, Bai et al. 2009).

[0013] These results indicate that PARG inhibitors and their polymorphic forms may provide a useful therapy for cancer. The present disclosure addresses these needs and provides related advantages as well.BRIEF SUMMARY

[0014] The present disclosure provides salt and free base crystalline forms of l-(5- (difluoromethyl)-l,3,4-thiadiazol-2-yl)-4-((3S,5S)-3,5-dimethylpiperazin-l-yl)-N-(l- methylcyclopropyl)-lH-indazole-6-sulfonamide (Compound 1), represented by the formula:(Compound 1).

[0015] In some aspects, provided herein is an HC1 salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is HC1 salt Form I. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0016] In some aspects, provided herein is a free base of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is free base Form I. In some embodiments, provided herein is a crystalline form of Compound 1 which is free base Form II. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0017] In some aspects, provided herein is a sulfate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is sulfate salt Form I. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0018] In some aspects, provided herein is a tosylate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is tosylate salt Form I. In some embodiments, provided herein is a crystalline form of Compound 1 which is tosylate salt Form II. In some embodiments, provided herein is a crystalline form of Compound 1 which is tosylate salt Form III. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0019] In some aspects, provided herein is a besylate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is besylate salt Form I. In some embodiments, provided herein is a crystalline form of Compound 1 which is besylate salt Form II. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0020] In some aspects, provided herein is a mesylate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is mesylate salt Form I. In some embodiments, provided herein is a crystalline form of Compound 1 which is mesylate salt Form II. In some embodiments, provided herein is a crystalline form of Compound 1 which is mesylate salt Form III. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0021] In some aspects, provided herein is a maleate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is maleate salt Form I. In some embodiments, provided herein is a crystalline form of Compound 1 which is maleate salt Form II. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0022] In some aspects, provided herein is a citrate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is citrate salt Form I. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0023] In some aspects, provided herein is a fumarate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is fumarate salt Form I. In some embodiments, provided herein is a crystalline form of Compound 1 which is fumarate salt Form II. In some embodiments, provided herein is a crystalline form of Compound 1 which is fumarate salt Form III. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0024] In some aspects, provided herein is a malate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is malate salt Form I. In some embodiments, provided herein is a crystalline form of Compound 1 which is malate salt Form II. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0025] In some aspects, provided herein is a succinate salt of Compound 1. In some embodiments, provided herein is a crystalline form of Compound 1 which is succinate salt Form I. In some embodiments, the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0026] Each of the provided crystalline forms can be further characterized as described herein.

[0027] In further aspects, provided herein are various solid state forms of Compound 1, comprising at least 50 percent by weight (wt%), 60 wt%, 70 wt%, 80 wt%, 90 wt%, 95 wt%, or 99 wt% of a particular crystalline form as described herein.

[0028] In further aspects, provided herein are pharmaceutical compositions of the crystalline forms of Compound 1 described herein.

[0029] In further aspects, provided herein are pharmaceutical compositions comprising a crystalline form of Compound 1 described herein or pharmaceutical compositions prepared using a crystalline form of Compound 1 described herein. Also provided are pharmaceutical compositions comprising a solid state form as described herein, or a pharmaceutical compositions prepared using a solid state form described herein. Pharmaceutical compositions will include one or more pharmaceutically acceptable excipients.

[0030] In additional aspects, provided herein are methods of inhibiting PARG in vivo in a patient, comprising administering to the patient an effective amount of a crystalline form ofCompound 1 described herein. In additional aspects, provided herein are methods of inhibiting PARG in vivo in a patient, comprising administering to the patient an effective amount of a solid state form of Compound 1 described herein.

[0031] In additional aspects, provided herein are methods of inhibiting PARG in vivo in a patient, comprising administering to the patient an effective amount of a pharmaceutical composition described herein, wherein the pharmaceutical composition i) comprises a crystalline form of Compound 1 described herein, ii) is prepared using a crystalline form of Compound 1 described herein, iii) comprises a solid state form as described herein, or iv) is prepared using a solid state form described herein.

[0032] In additional aspects, provided herein are methods of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a crystalline form of Compound 1 described herein. In additional aspects, provided herein are methods of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a solid state form of Compound 1 described herein.

[0033] In additional aspects, provided herein are methods of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a pharmaceutical composition described herein, wherein the pharmaceutical composition i) comprises a crystalline form of Compound 1 described herein, ii) is prepared using a crystalline form of Compound 1 described herein, iii) comprises a solid state form as described herein, or iv) is prepared using a solid state form described herein.

[0034] In additional aspects, provided herein are methods of treating a cancer resistant to one or more platins or one or more PARP inhibitors in a patient in need thereof, comprising administering to the patient an effective amount of a crystalline form of Compound 1 described herein. In additional aspects, provided herein are methods of treating a cancer resistant to one or more platins or one or more PARP inhibitors in a patient in need thereof, comprising administering to the patient an effective amount of a solid state form of Compound 1 described herein.

[0035] In additional aspects, provided herein are methods of treating a cancer resistant to one or more platins or one or more PARP inhibitors in a patient in need thereof, comprising administering to the patient an effective amount of a pharmaceutical composition described herein, wherein the pharmaceutical composition i) comprises a crystalline form of Compound 1 described herein, ii) is prepared using a crystalline form of Compound 1 described herein,iii) comprises a solid state form as described herein, or iv) is prepared using a solid state form described herein.

[0036] In additional aspects, provided herein are methods of treating and / or preventing a homologous recombinant deficient (HRD) cancer in a patient, comprising administering to the patient an effective amount of a crystalline form of Compound 1 described herein. In additional aspects, provided herein are methods of treating and / or preventing a homologous recombinant deficient (HRD) cancer in a patient, comprising administering to the patient an effective amount of a solid state form of Compound 1 described herein.

[0037] In additional aspects, provided herein are methods of treating and / or preventing a homologous recombinant deficient (HRD) cancer in a patient, comprising administering to the patient an effective amount of a pharmaceutical composition described herein, wherein the pharmaceutical composition i) comprises a crystalline form of Compound 1 described herein, ii) is prepared using a crystalline form of Compound 1 described herein, iii) comprises a solid state form as described herein, or iv) is prepared using a solid state form described herein.

[0038] In additional aspects, provided herein are methods of treating and / or preventing a cancer in a patient, where the cancer is characterized by a reduction or absence of BRCA1 and / or BRCA2 gene expression, the absence or mutation of BRCA1 and / or BRCA2 genes, or reduced function of BRCA1 and / or BRCA2 proteins, comprising administering to the patient an effective amount of a crystalline form of Compound 1 described herein. In additional aspects, provided herein are methods of treating and / or preventing a cancer in a patient, where the cancer is characterized by a reduction or absence of BRCA1 and / or BRCA2 gene expression, the absence or mutation of BRCA1 and / or BRCA2 genes, or reduced function of BRCA1 and / or BRCA2 proteins, comprising administering to the patient an effective amount of a solid state form of Compound 1 described herein.

[0039] In additional aspects, provided herein are methods of treating and / or preventing a cancer in a patient, where the cancer is characterized by a reduction or absence of BRCA1 and / or BRCA2 gene expression, the absence or mutation of BRCA1 and / or BRCA2 genes, or reduced function of BRCA1 and / or BRCA2 proteins, comprising administering to the patient an effective amount of a pharmaceutical composition described herein, wherein the pharmaceutical composition i) comprises a crystalline form of Compound 1 described herein, ii) is prepared using a crystalline form of Compound 1 described herein, iii) comprises a solid state form as described herein, or iv) is prepared using a solid state form described herein.

[0040] In additional aspects, the crystalline forms provided herein and pharmaceutical compositions thereof are useful in the treatment of cancer.

[0041] In additional aspects, provided herein are uses of the crystalline forms provided herein and pharmaceutical compositions thereof for the manufacture of a medicament for treating cancer.BRIEF DESCRIPTION OF THE DRAWINGS

[0042] FIG. 1 shows the X-ray powder diffraction (XRPD) pattern of free base Form I of Compound 1.

[0043] FIG. 2 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of free base Form I of Compound 1.

[0044] FIG. 3 shows a representative polarized light microscopy (PLM) image of free base Form I of Compound 1.

[0045] FIG. 4 shows the X-ray powder diffraction (XRPD) pattern of free base Form II of Compound 1.

[0046] FIG. 5 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of free base Form II of Compound 1.

[0047] FIG. 6 shows a representative polarized light microscopy (PLM) image of free base Form II of Compound 1.

[0048] FIG. 7 shows the X-ray powder diffraction (XRPD) pattern of HC1 salt Form I of Compound 1.

[0049] FIG. 8 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of HC1 salt Form I of Compound 1.

[0050] FIG. 9 shows dynamic vapor sorption (DVS) plot of HC1 salt Form I of Compound 1.

[0051] FIG. 10 shows a representative polarized light microscopy (PLM) image of HC1 salt Form I of Compound 1.

[0052] FIG. 11 shows the X-ray powder diffraction (XRPD) pattern of sulfate salt Form I of Compound 1.

[0053] FIG. 12 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of sulfate salt Form I of Compound 1.

[0054] FIG. 13 shows a representative polarized light microscopy (PLM) image of sulfate salt Form I of Compound 1.

[0055] FIG. 14 shows the X-ray powder diffraction (XRPD) pattern of tosylate salt Form I of Compound 1.

[0056] FIG. 15 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of tosylate salt Form I of Compound 1.

[0057] FIG. 16 shows a representative polarized light microscopy (PLM) image of tosylate salt Form I of Compound 1.

[0058] FIG. 17 shows the X-ray powder diffraction (XRPD) pattern of tosylate salt Form II of Compound 1.

[0059] FIG. 18 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of tosylate salt Form II of Compound 1.

[0060] FIG. 19 shows a representative polarized light microscopy (PLM) image of tosylate salt Form II of Compound 1.

[0061] FIG. 20 shows the X-ray powder diffraction (XRPD) pattern of tosylate salt Form III of Compound 1.

[0062] FIG. 21 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of tosylate salt Form III of Compound 1.

[0063] FIG. 22 shows dynamic vapor sorption (DVS) plot of tosylate salt Form III of Compound 1.

[0064] FIG. 23 shows a representative polarized light microscopy (PLM) image of tosylate salt Form III of Compound 1.

[0065] FIG. 24 shows the X-ray powder diffraction (XRPD) pattern of besylate salt Form I of Compound 1.

[0066] FIG. 25 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of besylate salt Form I of Compound 1.

[0067] FIG. 26 shows a representative polarized light microscopy (PLM) image of besylate salt Form I of Compound 1.

[0068] FIG. 27 shows the X-ray powder diffraction (XRPD) pattern of besylate salt Form II of Compound 1.

[0069] FIG. 28 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of besylate salt Form II of Compound 1.

[0070] FIG. 29 shows a representative polarized light microscopy (PLM) image of besylate salt Form II of Compound 1.

[0071] FIG. 30 shows the X-ray powder diffraction (XRPD) pattern of mesylate salt FormI of Compound 1.

[0072] FIG. 31 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of mesylate salt Form I of Compound 1.

[0073] FIG. 32 shows dynamic vapor sorption (DVS) plot of mesylate salt Form I of Compound 1.

[0074] FIG. 33 shows a representative polarized light microscopy (PLM) image of mesylate salt Form I of Compound 1.

[0075] FIG. 34 shows the X-ray powder diffraction (XRPD) pattern of mesylate salt FormII of Compound 1.

[0076] FIG. 35 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of mesylate salt Form II of Compound 1.

[0077] FIG. 36 shows a representative polarized light microscopy (PLM) image of mesylate salt Form II of Compound 1.

[0078] FIG. 37 shows the X-ray powder diffraction (XRPD) pattern of mesylate salt FormIII of Compound 1 .

[0079] FIG. 38 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of mesylate salt Form III of Compound 1.

[0080] FIG. 39 shows a representative polarized light microscopy (PLM) image of mesylate salt Form III of Compound 1.

[0081] FIG. 40 shows the X-ray powder diffraction (XRPD) pattern of maleate salt Form I of Compound 1.

[0082] FIG. 41 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of maleate salt Form I of Compound 1.

[0083] FIG. 42 shows a representative polarized light microscopy (PLM) image of maleate salt Form I of Compound 1.

[0084] FIG. 43 shows the X-ray powder diffraction (XRPD) pattern of maleate salt Form II of Compound 1.

[0085] FIG. 44 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of maleate salt Form II of Compound 1.

[0086] FIG. 45 shows a representative polarized light microscopy (PLM) image of maleate salt Form II of Compound 1.

[0087] FIG. 46 shows the X-ray powder diffraction (XRPD) pattern of citrate salt Form I of Compound 1.

[0088] FIG. 47 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of citrate salt Form I of Compound 1.

[0089] FIG. 48 shows a representative polarized light microscopy (PLM) image of citrate salt Form I of Compound 1.

[0090] FIG. 49 shows the X-ray powder diffraction (XRPD) pattern of fumarate salt FormI of Compound 1.

[0091] FIG. 50 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of fumarate salt Form I of Compound 1.

[0092] FIG. 51 shows a representative polarized light microscopy (PLM) image of fumarate salt Form I of Compound 1.

[0093] FIG. 52 shows the X-ray powder diffraction (XRPD) pattern of fumarate salt FormII of Compound 1.

[0094] FIG. 53 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of fumarate salt Form II of Compound 1.

[0095] FIG. 54 shows a representative polarized light microscopy (PLM) image of fumarate salt Form II of Compound 1.

[0096] FIG. 55 shows the X-ray powder diffraction (XRPD) pattern of fumarate salt Form III of Compound 1 .

[0097] FIG. 56 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of fumarate salt Form III of Compound 1.

[0098] FIG. 57 shows a representative polarized light microscopy (PLM) image of fumarate salt Form III of Compound 1.

[0099] FIG. 58 shows the X-ray powder diffraction (XRPD) pattern of malate salt Form I of Compound 1.

[0100] FIG. 59 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of malate salt Form I of Compound 1.

[0101] FIG. 60 shows a representative polarized light microscopy (PLM) image of malate salt Form I of Compound 1.

[0102] FIG. 61 shows the X-ray powder diffraction (XRPD) pattern of malate salt Form II of Compound 1.

[0103] FIG. 62 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of malate salt Form II of Compound 1.

[0104] FIG. 63 shows dynamic vapor sorption (DVS) plot of malate salt Form II of Compound 1.

[0105] FIG. 64 shows a representative polarized light microscopy (PLM) image of malate salt Form II of Compound 1.

[0106] FIG. 65 shows the X-ray powder diffraction (XRPD) pattern of succinate salt Form I of Compound 1.

[0107] FIG. 66 shows the differential scanning calorimetry (DSC) thermogram as well as the thermal gravimetric analysis (TGA) of succinate salt Form I of Compound 1.

[0108] FIG. 67 shows a representative polarized light microscopy (PLM) image of succinate salt Form I of Compound 1.DETAILED DESCRIPTION OF THE INVENTIONI. General

[0109] The present disclosure provides crystalline forms of Compound 1 . These forms are characterized by an X-ray powder diffraction (XRPD) pattern. Selected crystalline forms are further characterized by a differential scanning calorimetry (DSC), a thermal gravimetric analysis (TGA), a dynamic vapor sorption analysis (DVS), and / or a polarized light microscope (PLM) profile. The present disclosure further provides pharmaceutical compositions of the crystalline forms of Compound 1 described herein. In some embodiments, the present disclosure provides a pharmaceutical composition described herein, wherein the pharmaceutical composition i) comprises a crystalline form of Compound 1 described herein, ii) is prepared using a crystalline form of Compound 1 described herein, iii) comprises a solid state form as described herein, or iv) is prepared using a solid state form described herein.

[0110] The present disclosure further provides methods of inhibiting PARG in vivo in a patient, the method comprising administering to the patient a therapeutically effective amount of a crystalline form of Compound 1 described herein. The present disclosure further provides methods of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a crystalline form of Compound 1 described herein. The present disclosure further provides methods of treating a cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a crystalline form of Compound 1 described herein. The present disclosure further provides methods of treating a cancer resistant to one or more platins or one or more PARP inhibitors in a patient in need thereof, the method comprising administering to the patient an effective amount of a crystalline form of Compound 1 described herein. The present disclosure further provides methods of treating and / or preventing a homologous recombinant deficient (HRD) cancer in a patient, the method comprising administering to the patient a therapeutically effective amount of a crystalline form of Compound 1 described herein. The present disclosure further provides methods of treating and / or preventing a cancer in a patient, where the cancer is characterized by a reduction or absence of BRCA1 and / or BRCA2 gene expression, the absence or mutation of BRCA1 and / or BRCA2 genes, or reduced function of BRCA1 and / or BRCA2 proteins, the method comprising administering tothe individual a therapeutically effective amount of a crystalline form of Compound 1 described herein.

[0111] The present disclosure further provides methods of inhibiting PARG in vivo in a patient, the method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition described herein. The present disclosure further provides methods of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a pharmaceutical composition described herein. The present disclosure further provides methods of treating a cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition described herein. The present disclosure further provides methods of treating a cancer resistant to one or more platins or one or more PARP inhibitors in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition described herein. The present disclosure further provides methods of treating and / or preventing a homologous recombinant deficient (HRD) cancer in a patient, the method comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition described herein. The present disclosure further provides methods of treating and / or preventing a cancer in a patient, where the cancer is characterized by a reduction or absence of BRCA1 and / or BRCA2 gene expression, the absence or mutation of BRCA1 and / or BRCA2 genes, or reduced function of BRCA1 and / or BRCA2 proteins, the method comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition described herein.II. Definitions

[0112] “Substantially free” refers to that an amount of 10% or less of another form is present in a particular desired form, preferably 9%, 8.5%, 8%, 7.5%, 7%, 6.5%, 6%, 5.5%, 5%, 4.5%, 4%, 3.5%, 3%, 2.5%, 2%, 1.5%, 1%, 0.5%, or less of another form.

[0113] “Crude” refers to a mixture including a desired compound (e.g., the compound of Formula (I)) and at least one other species (e.g., a solvent, a reagent such as an acid or base, a starting material, or a byproduct of a reaction giving rise to the desired compound).

[0114] “Solvate” refers to a compound provided herein or a salt thereof that binds to a stoichiometric or non-stoichiometric amount of solvent by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.

[0115] “Hydrate” refers to a compound that is complexed to a stoichiometric or non- stoichiometric amount of water. The compounds of the present invention can be complexed with from 'Z> or 1 to 10 water molecules. For example, the compounds of the present invention can be complexed with ' / i water molecule, the compounds of the present invention can be complexed with 1 water molecule, or the compounds of the present invention can be complexed with 2 water molecules.

[0116] “Crystalline form” refers to a solid form of a compound wherein the constituent molecules are packed in a regularly ordered, repeating pattern. A crystalline form can include triclinic, monoclinic, orthorhombic, tetragonal, trigonal, hexagonal, and cubic crystal geometries. A crystalline form can include one or more regions, i.e., grains, with distinct crystal boundaries. A crystalline solid can include two or more crystal geometries.

[0117] “Amorphous form” refers to a solid form of a compound having no definite crystal structure, i.e., lacking a regularly ordered, repeating pattern of constituent molecules.

[0118] “FeSSIF” stands for Fed State Simulated Intestinal Fluid. “FaSSIF” stands for Fasted State Simulated Intestinal Fluid. “SGF” stands for Simulated Gastric Fluid.

[0119] “About” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In some embodiments, the term “about” means within a standard deviation using measurements generally acceptable in the art. In some embodiments, “about” means a range extending to + / - 10% of the specified value.

[0120] “Pharmaceutically acceptable salts” as used herein is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds disclosed herein contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and thelike. Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally- occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N’- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogen carbonic, phosphoric, monohydrogen phosphoric, dihydrogen phosphoric, sulfuric, monohydrogen sulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0121] “Compound 1” is a chemical compound having an IUPAC name of l-(5- (difluoromethyl)- 1 ,3 ,4-thiadiazol-2-yl)-4-((3 S,5S)-3 ,5 -dimethylpiperazin- 1 -yl)-N-( 1 - methylcyclopropyl)- lH-indazole-6-sulfonamide, and the structure shown below:(Compound 1).

[0122] “Free base of Compound 1” or “Compound 1 in free base” refers to Compound 1 represented by the formula:(Compound 1).

[0123] The term “treating” or “treatment’ encompasses both disease-modifying treatment and symptomatic treatment, either of which may be prophylactic (i.e., before the onset of symptoms, in order to prevent, delay or reduce the severity of symptoms) or therapeutic (i.e., after the onset of symptoms, in order to reduce the severity and / or duration of symptoms).

[0124] The term “individual” or “patient” or “individual in need thereof’ or “patient in need thereof’ refers to mammals, which includes primates (especially humans), domesticated companion animals (such as dogs, cats, horses, and the like) and livestock (such as cattle, pigs, sheep, and the like), with dosages as described herein. In some embodiments, the term “individual,” “patient” or “individual in need thereof’ or “patient in need thereof’ refers to a human. In some embodiments, the human is an adult.

[0125] An “effective amount” or a “therapeutically effective amount” is an amount sufficient to accomplish a stated purpose (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, reduce one or more symptoms of a disease or condition). An example of an “effective amount” is an amount sufficient to contribute to the treatment, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). in. Detailed Description of Embodiments

[0126] Provided herein are various crystalline forms of Compound 1, including free base and salt forms, pharmaceutical compositions comprising the same, methods of their use, andmethods of preparing the salt forms. Certain crystalline forms may be hydrates, solvates, or anhydrous forms of Compound 1. Certain crystalline forms may be hydrates, solvates, or anhydrous forms of Compound 1 in free base. Certain crystalline forms may be hydrates, solvates, or anhydrous forms of Compound 1 in salt forms.

[0127] Methods for collection of XRPD data are known in the art, and any such methods can be used for characterizing the crystalline forms described herein. For example, the X-ray powder diffraction patterns described herein can be generated using Cu Kai radiation.

[0128] In some embodiments, the crystalline forms described herein are further characterized by a differential scanning calorimetry (DSC) thermogram. In some embodiments, a DSC thermogram is recorded using a sample weight of about 1-3 mg, which is subjected to temperatures ranging from 25°C to 300°C using a ramp of 10°C / min.

[0129] In some embodiments, the crystalline form described herein is further characterized by a thermal gravimetric analysis (TGA). In some embodiments, a TGA thermogram is recorded using a sample weight of about 1-5 mg, which is subjected to temperatures ranging from room temperature to 300°C using a ramp of 10°C / min.

[0130] In some embodiments, the crystalline form described herein is further characterized by a polarized light microscope (PLM) profile.

[0131] In some embodiments, the crystalline form described herein is further characterized by a dynamic vapor sorption (DVS) profile. In some embodiments, a DVS is recorded according to the method as described herein.A. Free Base Forms of Compound 1

[0132] In some embodiments, the crystalline form is a free base form of Compound 1. In some embodiments, the crystalline form is free base Form I. In some embodiments, the crystalline form is free base Form II. i. Free Base Form I

[0133] In one embodiment, the present disclosure provides free base Form I of Compound 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0 and 18.3 degrees 29 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD)patern comprising peaks at 9.0, 16.4, and 18.3 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 16.4, 18.0, and 18.3 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 16.4, 18.0, 18.3, and 19.4 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 12.7, 16.4, 18.0, 18.3, and 19.4 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 12.7, 16.4, 18.0, 18.3, 18.9, and 19.4 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 12.7, 13.7, 16.4, 18.0,18.3. 18.9, and 19.4 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 12.7,13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 11.5, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 11.5, 12.7, 13.7, 16.4, 17.2, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 9.0, 11.5, 12.2, 12.7, 13.7, 16.4, 17.2, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

[0134] In some embodiments, free base Form I is characterized by an XRPD patern comprising three peaks selected from 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an XRPD patern comprising three or more peaks selected from 9.0, 12.7, 13.7, 16.4, 18.0, 18.3,18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an XRPD patern comprising four peaks selected from 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an XRPD patern comprising five peaks selected from 9.0,12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

[0135] In some embodiments, free base Form I is characterized by an XRPD patern further comprising one or more peaks (such as one, two, or three peaks) selected from 23.2, 23.5, and24.6 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes a peak at 24.6 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or two peaks selected from 23.5 and24.6 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 22.5, 23.2, 23.5, 24.6, and 27.8 degrees 20 (± 0.2 degrees 20). For example, in some embodiments, free base Form I is characterized by an XRPD pattern comprising peaks at 9.0, 16.4, 18.3, 23.5, and24.6 degrees 20 (± 0.2 degrees 20). For example, in some embodiments, free base Form I is characterized by an XRPD pattern comprising peaks at 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, 23.5, and 24.6 degrees 20 (± 0.2 degrees 20).

[0136] In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 1.

[0137] In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 1. In some embodiments, free base Form I is characterized by anX-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 1.

[0138] In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 1.

[0139] In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 1. In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 1.

[0140] In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 18.3, and 24.6 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 16.4, 18.3, and 24.6 degrees 20 (± 0.2 degrees 20).

[0141] In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 16.4, 18.3, 23.5, and 24.6 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 12.7, 13.7, 18.0, 18.9, and 19.4 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, 23.5, and 24.6 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, 19.7, 23.5, and 24.6 degrees 20 (± 0.2 degrees 20).

[0142] In some embodiments, free base Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 1.

[0143] In some embodiments, free base Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 200°C. In some embodiments, free base Form I is further characterized by a differential scanning calorimetry (DSC) thermogram including an endotherm onset temperature of about 199°C and an endothermic peak at about 200°C.

[0144] In some embodiments, free base Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 2.

[0145] In some embodiments, free base Form I is further characterized by no weight loss upon heating prior to decomposition, as measured by a thermal gravimetric analysis (TGA). In some embodiments, free base Form I is further characterized by substantially no weight loss upon heating prior to decomposition, as measured by a thermal gravimetric analysis (TGA). In some embodiments, free base Form I is further characterized by a weight loss of no greater than 5%, 4%, 3%, 2%, or 1% by weight upon heating prior to decomposition, as measured by a thermal gravimetric analysis (TGA).

[0146] In some embodiments, free base Form I is further characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 2.

[0147] In some embodiments, free base Form I is further characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 3.

[0148] In some embodiments, free base Form I is substantially free of other crystalline or amorphous forms. ii. Free Base Form II

[0149] In one embodiment, the present disclosure provides free base Form II of Compound 1. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3 and 18.7 degrees 20 (± 0.2 degrees 29). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, and 18.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, 17.1, and 18.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, 17.1, 18.7, and 19.5 degrees 20 (± 0.2 degrees 29). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, 16.4, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 13.4, 15.6, 16.4, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3,13.4, 15.6, 16.1, 16.4, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 13.4, 14.1, 15.6, 16.1, 16.4, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 13.4, 14.1, 15.6, 16.1,16.4, 17.1, 18.7, 19.5, 19.7, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 13.4, 14.1, 15.6, 16.1, 16.4, 17.1, 17.4, 18.7, 19.5, 19.7, and 20.0 degrees 20 (± 0.2 degrees 20).

[0150] In some embodiments, free base Form II is characterized by an XRPD pattern comprising three peaks selected from 12.3, 15.6, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an XRPD pattern comprising four peaks selected from 12.3, 15.6, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an XRPD pattern comprising five peaks selected from 12.3, 15.6, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 20).

[0151] In some embodiments, free base Form II is characterized by an XRPD pattern further comprising one or more peaks (such as one, two, three, four, five, six, or seven peaks) selected from 20.2, 20.7, 23.0, 25.0, 25.7, 26.5, and 31.4 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an XRPD pattern further comprising a peak at 20.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an XRPD pattern further comprising one or two peaks selected from 20.2 and 20.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 20.2, 20.7, and 25.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 20.2, 20.7, 23.0, and 25.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 20.2, 20.7, 23.0, 25.7, and 26.5 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 20.2, 20.7, 23.0, 25.0, 25.7, and 26.5 degrees 20 (± 0.2 degrees 20). For example, in some embodiments, free base Form II is characterized by an XRPD pattern comprising peaks at 12.3, 15.6, 17.1, 18.7, and 20.7 degrees 20 (± 0.2 degrees 20). For example, in some embodiments, free base Form II is characterized by an XRPD pattern comprising peaks at 12.3, 15.6, 17.1, 18.7, 19.5, 19.7, 20.2, 20.7, 23.0, and 25.7 degrees 20 (± 0.2 degrees 20).

[0152] In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 2. In some embodiments, free base Form II is characterized by anX-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 2.

[0153] In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 2.

[0154] In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD)patern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 2.

[0155] In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 2. In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 2.

[0156] In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 12.3, 15.6, and 18.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 12.3, 15.6, 18.7, and 20.7 degrees 20 (± 0.2 degrees 20).

[0157] In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) patern comprising peaks at 12.3, 15.6, 17.1, 18.7, and 20.7 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD patern further comprises peaks at 19.5, 19.7, 20.2, 23.0, and 25.7 degrees 20 (± 0.2 degrees 20). In some embodiments, free baseForm II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, 17.1, 18.7, 19.5, 19.7, 20.2, 20.7, 23.0, and 25.7 degrees 20 (± 0.2 degrees 20).

[0158] In some embodiments, free base Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 4.

[0159] In some embodiments, free base Form II is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic peak at about 148 °C, and / or a second endothermic peak at about 198 °C. In some embodiments, free base Form II is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic onset and peak at about 143 °C and 148 °C, respectively, and / or a second endothermic onset and peak at about 197 °C and 198 °C, respectively. In some embodiments, free base Form II is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic onset and peak at about 143 °C and about 148 °C, respectively, and / or a second endothermic onset and peak at about 197 °C and about 198 °C, respectively.

[0160] In some embodiments, free base Form II is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 5.

[0161] In some embodiments, free base Form II is characterized by 15.1% weight loss upon heating to 158 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, free base Form II is characterized by about 15.1% weight loss upon heating to about 158 °C, as measured by a thermal gravimetric analysis (TGA).

[0162] In some embodiments, free base Form II is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 5.

[0163] In some embodiments, free base Form II is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 6.

[0164] In some embodiments, free base Form II is substantially free of other crystalline or amorphous forms.B. Salt Forms of Compound 1

[0165] The present disclosure provides various salt forms of Compound 1 including an HC1 salt, sulfate salt, tosylate salt, besylate salt, mesylate salt, maleate salt, citrate salt, fumarate salt, malate salt, and succinate salt. The single crystalline forms of the described salts are, in certain embodiments, substantially free of other crystalline or amorphous forms. Thecrystalline forms of the described salts are, in certain embodiments, substantially free of other crystalline or amorphous forms.

[0166] Particular salts disclosed herein can exist in one or more polymorphic forms. Individual polymorphic forms of the described salts are identified as Form I, Form II, and Form III. i. HCl salt of Compound 1 (Form I)

[0167] In some aspects, the crystalline form is an HCl salt of Compound 1. In some embodiments, the crystalline form is HCl salt Form I. In some embodiments, HCl salt Form I is an anhydrate.

[0168] In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 13.2 and 13.7 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 13.2 and 17.7 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 13.2, 13.7, and 17.7 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 11.7,13.2, 13.7, and 17.7 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 11.7, 13.2, 13.7, 17.7, and 18.4 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 11.7, 13.2, 13.7, 17.2, and 17.7 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 11.7, 13.2, 13.7, 17.2, 17.7, and 18.4 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 11.7,13.2, 13.7, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 11.7, 13.2, 13.7,15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 7.0, 11.7, 13.2, 13.7,15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 7.0, 8.0, 11.7, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 7.0, 11.7, 12.2, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20).In some embodiments, HCl salt Form I is characterized by an XRPD pattern comprising peaks at 7.0,8.0, 11.7, 12.2, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, HC1 salt Form I is characterized by an XRPD pattern comprising peaks at 7.0, 8.0, 11.7, 12.2, 13.2, 13.5, 13.7, 15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20).

[0169] In some embodiments, HC1 salt Form I is characterized by an XRPD pattern comprising three peaks selected from 11.7, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 19.9. In some embodiments, HC1 salt Form I is characterized by an XRPD pattern comprising three or more peaks selected from 11.7, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 19.9. In some embodiments, HC1 salt Form I is characterized by an XRPD pattern comprising four peaks selected from 11.7, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 19.9. In some embodiments, HC1 salt Form I is characterized by an XRPD pattern comprising five peaks selected from 11.7, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 19.9.

[0170] In some embodiments of HC1 salt Form I, the X-ray powder diffraction pattern further includes one or more peaks (such as one, two, three, four, five, six, seven, eight, nine, ten, or eleven peaks) selected from 20.6, 20.9, 21.2, 21.7, 22.3, 24.3, 25.0, 25.3, 25.6, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes a peak at 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or two peaks selected from 26.1 and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or more peaks selected from 24.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or more peaks selected from 20.9, 24.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or more peaks selected from 20.9, 24.3, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or more peaks selected from 20.6, 20.9, 24.3, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or more peaks selected from 20.6, 20.9, 21.2, 24.3, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or more peaks selected from 20.6, 20.9, 21.2, 24.3, 25.0, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes one or more peaks selected from 20.6, 20.9, 21.2, 21.7, 24.3, 25.0, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the X-ray powder diffraction pattern further includes oneor more peaks selected from 20.6, 20.9, 21.2, 21.7, 24.3, 25.0, 25.3, 25.6, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). For example, in some embodiments, HC1 salt Form I is characterized by an XRPD pattern comprising peaks at 13.2, 13.7, 17.7, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). For example, in some embodiments, HC1 salt Form I is characterized by an XRPD pattern comprising peaks at 13.2, 13.7, 17.7, 20.6, 20.9, 21.2, 24.3, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

[0171] In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in able 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X- ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 3.

[0172] In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 3. In some embodiments, HC1salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least 10 peaks having a relative intensity of at least 15% as listed in Table 3.

[0173] In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least 10 peaks having a relative intensity of at least 20% as listed in Table 3.

[0174] In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed inTable 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 30% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 30% as listed in Table 3. In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least 10 peaks having a relative intensity of at least 30% as listed in Table 3.

[0175] In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 13.7, 17.7, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 13.7, 17.7, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 13.7, 17.7, 24.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 13.7, 17.7, 20.6, 20.9, 21.2, 24.3, 25.0, 25.3,26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 13.7, 17.7,20.6, 20.9, 21.2, 21.7, 24.3, 25.0, 25.3, 25.6, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.7, 13.7, 17.2, 17.7, 18.4, 20.6, 20.9, 21.2, 21.7, 24.3, 25.0, 25.3, 25.6, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at11.7, 13.7, 15.3, 17.2, 17.7, 18.4, 20.0, 20.6, 20.9, 21.2, 21.7, 24.3, 25.0, 25.3, 25.6, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

[0176] In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 13.2, 13.7, 17.7, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 20.6, 20.9, 21.2, 24.3, and 25.3 degrees 20 (± 0.2 degrees 20). In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at13.2, 13.7, 17.7, 20.6, 20.9, 21.2, 24.3, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

[0177] In some embodiments, HC1 salt Form I is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 7.

[0178] In some embodiments, HC1 salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including no endothermic peak prior to decomposition at about 300 °C.

[0179] In some embodiments, HC1 salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 8.

[0180] In some embodiments, HC1 salt Form I is characterized by no weight loss upon heating prior to decomposition, as measured by a thermal gravimetric analysis (TGA). In some embodiments, HC1 salt Form I is characterized by no substantial weight loss upon heating prior to decomposition, as measured by a thermal gravimetric analysis (TGA). In some embodiments, HC1 salt Form I is characterized by a weight loss of no greater than 5%, 4%, 3%, 2%, 1%, or 0.5% by weight upon heating prior to decomposition, as measured by a thermal gravimetric analysis (TGA).

[0181] In some embodiments, HC1 salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 8.

[0182] In some embodiments, HC1 salt Form I is characterized by a weight gain of about 0.5% after undergoing a dynamic vapor sorption profile cycle from about 0% relative humidity (RH) to about 90% RH at 25 °C.

[0183] In some embodiments, HC1 salt Form I is characterized by a dynamic vapor sorption (DVS) profile substantially as shown in FIG. 9.

[0184] In some embodiments, HC1 salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 10.

[0185] In some embodiments, HC1 salt Form I is substantially free of other crystalline or amorphous forms. ii. Sulfate salt of Compound 1 (Form I)

[0186] In some aspects, the crystalline form is a sulfate salt of Compound 1. In some embodiments, the crystalline form is sulfate salt Form I. In some embodiments, sulfate salt Form I is a hydrate.

[0187] In one embodiment, the present disclosure provides sulfate salt Form I of Compound 1. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.0, 8.5, 13.2, 15.6, and 16.1 degrees 20 (± 0.2 degrees 20). In some embodiments, sulfate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 8.8, 12.9, 15.0, 17.2, and 19.0 degrees 20 (± 0.2 degrees 20). In some embodiments, sulfate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 20.2, 22.1, 24.3, 25.1, and 26.7degrees 20 (± 0.2 degrees 20).

[0188] In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.0, 8.5, 13.2, 15.6, and 16.1 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 8.8, 12.9, 15.0, 19.0, and 24.3 degrees 20 (± 0.2 degrees 20). In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.0, 8.5, 8.8, 12.9, 13.2, 15.0, 15.6, 16.1, 19.0, and 24.3 degrees 20 (± 0.2 degrees 20).

[0189] In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 4.

[0190] In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 4. In someembodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 4.

[0191] In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 4.

[0192] In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relativeintensity of at least 30% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 4. In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 30% as listed in Table 4.

[0193] In some embodiments, sulfate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 11.

[0194] In some embodiments, sulfate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including a first endotherm peak 118 °C, a second endotherm peak at 220 °C, an exotherm peak at 231 °C, and / or a third endotherm peak at 279 °C. In some embodiments, sulfate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including a first endotherm peak at about 118 °C, a second endotherm peak at about 220 °C, an exotherm peak at about 231 °C, and / or a third endotherm peak at about 279 °C. In some embodiments, sulfate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including a first endotherm onset and peak at 78 °C and 118 °C, respectively; a second endotherm onset and peak at 206 °C and 220 °C, respectively; an exotherm onset and peak at 227 °C and 231 °C, respectively; and / or a third endotherm onset and peak at 273 °C and 279 °C, respectively. In some embodiments, sulfate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including a first endotherm onset and peak at about 78 °C and about 118 °C, respectively; a second endotherm onset and peak at about 206 °C and about 220 °C, respectively; an exotherm onset and peak at about 227 °C and about 231 °C, respectively; and / or a third endotherm onset and peak at about 273 °C and about 279 °C, respectively.

[0195] In some embodiments, sulfate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 12.

[0196] In some embodiments, sulfate salt Form I is characterized by 2.8% weight loss upon heating to 130 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, sulfate salt Form I is characterized by about 2.8% weight loss upon heating to about 130 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, sulfate salt Form I is characterized by weight loss not greater than about 10%, 5%, 4%, or 3% by weight upon heating to about 130 °C, as measured by a thermal gravimetric analysis (TGA).

[0197] In some embodiments, sulfate salt Form I is characterized by a thermal gravimetric

[0198] In some embodiments, sulfate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 13.

[0199] In some embodiments, sulfate salt Form I is substantially free of other crystalline or amorphous forms.Hi. Tosylate salt of Compound 1 (Form I)

[0200] In some aspects, the crystalline form is a tosylate salt of Compound 1. In some embodiments, the crystalline form is tosylate salt Form I. In some embodiments, tosylate salt Form I is an anhydrate.

[0201] In one embodiment, the present disclosure provides tosylate salt Form I of Compound 1. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.8, 9.6, 14.5, 18.2, and 19.5 degrees 20 (± 0.2 degrees 20). In some embodiments, tosylate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 4.7, 11.7, 13.7, 15.5, and 15.9 degrees 20 (± 0.2 degrees 20). In some embodiments, tosylate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 21.4,22.8, 24.0, 24.3, and 29.3 degrees 20 (± 0.2 degrees 20).

[0202] In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.6, 14.5, 18.2, 19.5, and 24.3 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 6.8, 21.4, 22.8, 24.0, and 29.3 degrees 20 (± 0.2 degrees 20). In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at6.8, 9.6, 14.5, 18.2, 19.5, 21.4, 22.8, 24.0, 24.3, and 29.3 degrees 20 (± 0.2 degrees 20).

[0203] In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 5.

[0204] In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 5.

[0205] In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relativeintensity of at least 20% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 5.

[0206] In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 5. In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 5.

[0207] In some embodiments, tosylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 14.

[0208] In some embodiments, tosylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 231 °C. In some embodiments, tosylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 222 °C and an endothermic peak at about 231°C.

[0209] In some embodiments, tosylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 15.

[0210] In some embodiments, tosylate salt Form I is characterized by 1.2% weight loss upon heating from 110 °C to 230 °C, as measured by a thermal gravimetric analysis (TGA).In some embodiments, tosylate salt Form I is characterized by about 1.2% weight loss upon heating from about 110 °C to about 230 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, tosylate salt Form I is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, or 2% by weight upon heating from about 110 °C to about 230 °C, as measured by a thermal gravimetric analysis (TGA).

[0211] In some embodiments, tosylate salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 15.

[0212] In some embodiments, tosylate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 16.

[0213] In some embodiments, tosylate salt Form I is substantially free of other crystalline or amorphous forms. iv. Tosylate salt of Compound 1 (Form II)

[0214] In some aspects, the crystalline form is a tosylate salt of Compound 1. In some embodiments, the crystalline form is tosylate salt Form II. In some embodiments, tosylate salt Form II is anhydrate.

[0215] In one embodiment, the present disclosure provides tosylate salt Form II of Compound 1. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.7, 14.3, 15.4, 17.3, and 19.1degrees 29 (± 0.2 degrees 20). In some embodiments, tosylate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 9.1, 10.2, 13.0, 17.0, and 18.4 degrees 20 (± 0.2 degrees 20). In some embodiments, tosylate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 20.1, 20.5, 23.8, 24.2, and 26.2 degrees 20 (± 0.2 degrees 20).

[0216] In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.7, 15.4, 17.3, 20.1, and 24.2 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 14.3, 17.0, 19.1, 20.5, and 26.2 degrees 20 (± 0.2 degrees 20). In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.7, 14.3, 15.4, 17.0, 17.3, 19.1, 20.1, 20.5, 24.2, and 26.2 degrees 20 (± 0.2 degrees 20).

[0217] In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 6.

[0218] In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 6.

[0219] In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relativeintensity of at least 20% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 6.

[0220] In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 6. In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 6.

[0221] In some embodiments, tosylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 17.

[0222] In some embodiments, tosylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 229 °C. In some embodiments, tosylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 223 °C and an endothermic peak at about 229 °C.

[0223] In some embodiments, tosylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 18.

[0224] In some embodiments, tosylate salt Form II is characterized by 1.4% weight loss upon heating from 90 °C to 230 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, tosylate salt Form II is characterized by about 1.4% weight loss upon heating from about 90 °C to about 230 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, tosylate salt Form II is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, or 2% by weight upon heating from about 90 °C to about 230 °C, as measured by a thermal gravimetric analysis (TGA).

[0225] In some embodiments, tosylate salt Form II is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 18.

[0226] In some embodiments, tosylate salt Form II is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 19.

[0227] In some embodiments, tosylate salt Form II is substantially free of other crystalline or amorphous forms. v. Tosylate salt of Compound 1 (Form III)

[0228] In some aspects, the crystalline form is a tosylate salt of Compound 1. In some embodiments, the crystalline form is tosylate salt Form III. In some embodiments, tosylate salt Form III is an anhydrate.

[0229] In one embodiment, the present disclosure provides tosylate salt Form III of Compound 1. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.9, 14.5, 15.5, 18.2, and 19.5 degrees 20 (± 0.2 degrees 20). In some embodiments, tosylate salt Form III is characterized by an XRPD pattern further comprising one or more peaks selected from 9.7, 14.1, 14.9, 16.0, and 16.9 degrees 20 (± 0.2 degrees 20). In some embodiments, tosylate salt Form III ischaracterized by an XRPD pattern further comprising one or more peaks selected from 21.2,21.4, 22.0, 24.0, and 24.4 degrees 20 (± 0.2 degrees 20).

[0230] In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 18.2, 19.5, 21.2, 22.0, and 24.0 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 6.9,14.5, 15.5, 21.4, and 24.4 degrees 20 (± 0.2 degrees 20). In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.9, 14.5, 15.5, 18.2, 19.5, 21.2, 21.4, 22.0, 24.0, and 24.4 degrees 20 (± 0.2 degrees 20).

[0231] In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 7.

[0232] In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peakshaving a relative intensity of at least 15% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 7.

[0233] In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 7.

[0234] In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at leastfour peaks having a relative intensity of at least 30% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in able 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 7. In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 7.

[0235] In some embodiments, tosylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 20.

[0236] In some embodiments, tosylate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 222 °C. In some embodiments, tosylate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 206 °C and an endothermic peak at about 222 °C.

[0237] In some embodiments, tosylate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 21.

[0238] In some embodiments, tosylate salt Form III is characterized by 2.6% weight loss upon heating from about 110 °C to about 222 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, tosylate salt Form III is characterized by about 2.6% weight loss upon heating from about 110 °C to about 222 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, tosylate salt Form III is characterized by a weight loss loss of no greater than about 10%, 5%, 4%, or 3% by weight upon heating from about 110 °C to about 222 °C, as measured by a thermal gravimetric analysis (TGA).

[0239] In some embodiments, tosylate salt Form III is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 21.

[0240] In some embodiments, tosylate salt Form III is characterized by a weight gain of about 3.2% after undergoing a dynamic vapor sorption profile cycle from about 0% relative humidity (RH) to about 90% RH at 25 °C.

[0241] In some embodiments, tosylate salt Form III is characterized by a dynamic vapor sorption (DVS) profile substantially as shown in FIG. 22.

[0242] In some embodiments, tosylate salt Form III is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 23.

[0243] In some embodiments, tosylate salt Form III is substantially free of other crystalline or amorphous forms. vi. Besylate salt of Compound 1 (Form I)

[0244] In some aspects, the crystalline form is a besylate salt of Compound 1. In some embodiments, the crystalline form is besylate salt Form I. In some embodiments, besylate salt Form I is anhydrate.

[0245] In one embodiment, the present disclosure provides besylate salt Form I of Compound 1. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.8, 14.5, 15.4, 17.3, and 19.1 degrees 20 (± 0.2 degrees 20). In some embodiments, besylate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 15.0, 15.9, 17.7, 18.3, and 19.6 degrees 20 (± 0.2 degrees 20). In some embodiments, besylate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 20.3,20.8, 24.0, 25.2, and 26.0 degrees 20 (± 0.2 degrees 20).

[0246] In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.8, 17.3, 19.1, 24.0, and 25.2 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 14.5, 15.4, 17.7, 20.3, and 26.0 degrees 20 (± 0.2 degrees 20). In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at6.8, 14.5, 15.4, 17.3, 17.7, 19.1, 20.3, 24.0, 25.2, and 26.0 degrees 20 (± 0.2 degrees 20).

[0247] In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 8.

[0248] In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 8.

[0249] In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-raypowder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 8.

[0250] In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 30% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 30% as listed in Table 8. In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 30% as listed in Table 8.

[0251] In some embodiments, besylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 24.

[0252] In some embodiments, besylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 202 °C. In some embodiments, besylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 190 °C and an endothermic peak at about 202 °C.

[0253] In some embodiments, besylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 25.

[0254] In some embodiments, besylate salt Form I is characterized by 0.6% weight loss upon heating from 100 °C to 210 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, besylate salt Form I is characterized by about 0.6% weight loss upon heating from about 100 °C to about 210 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, besylate salt Form I is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, 2%, or 1% by weight upon heating from about 100 °C to about 210 °C, as measured by a thermal gravimetric analysis (TGA).

[0255] In some embodiments, besylate salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 25.

[0256] In some embodiments, besylate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 26.

[0257] In some embodiments, besylate salt Form I is substantially free of other crystalline or amorphous forms. vii. Besylate salt of Compound 1 (Form II)

[0258] In some aspects, the crystalline form is a besylate salt of Compound 1. In some embodiments, the crystalline form is besylate salt Form II. In some embodiments, besylate salt Form II is an anhydrate.

[0259] In one embodiment, the present disclosure provides besylate salt Form II of Compound 1. In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 7.6, 15.2, 15.7, 19.2, and 19.7 degrees 20 (± 0.2 degrees 20). In some embodiments, besylate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 9.0, 10.0, 12.4, 14.7, and 18.1degrees 20 (± 0.2 degrees 20). In some embodiments, besylate salt Form II ischaracterized by an XRPD pattern further comprising one or more peaks selected from 10.4,20.1, 22.9, 25.0, and 26.5 degrees 20 (± 0.2 degrees 20).

[0260] In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 7.6, 15.2, 19.2, 22.9, and 26.5 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 15.7,18.1, 19.7, 20.1, and 25.0 degrees 20 (± 0.2 degrees 20). In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 7.6, 15.2, 15.7, 18.1, 19.2, 19.7, 20.1, 22.9, 25.0, and 26.5 degrees 20 (± 0.2 degrees 20).

[0261] In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 9. In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 9. In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 9. In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 9. In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 9.

[0262] In some embodiments, besylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 27.

[0263] In some embodiments, besylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 165 °C. In some embodiments, besylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 154°C and an endothermic peak at about 165 °C.

[0264] In some embodiments, besylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 28

[0265] In some embodiments, besylate salt Form II is characterized by 0.5% weight loss upon heating from 64 °C to 185 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, besylate salt Form II is characterized by about 0.5% weight loss upon heating from about 64 °C to about 185 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, besylate salt Form II is characterized by a weight loss of nogreater than about 10%, 5%, 4%, 3%, 2%, or 1% by weight upon heating from about 64 °C to about 185 °C, as measured by a thermal gravimetric analysis (TGA).

[0266] In some embodiments, besylate salt Form II is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 28.

[0267] In some embodiments, besylate salt Form II is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 29.

[0268] In some embodiments, besylate salt Form II is substantially free of other crystalline or amorphous forms. viii. Mesylate salt of Compound 1 (Form I)

[0269] In some aspects, the crystalline form is a mesylate salt of Compound 1. In some embodiments, the crystalline form is mesylate salt Form I. In some embodiments, mesylate salt Form I is an anhydrate.

[0270] In one embodiment, the present disclosure provides mesylate salt Form I of Compound 1. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.2, 17.0, 18.0, 18.6, and 19.3 degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 11.0, 11.9, 12.7,15.1, and 17.5 degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 20.7,21.2, 22.1, 24.1, and 25.0 degrees 20 (± 0.2 degrees 20).

[0271] In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.2, 17.0, 18.6, 22.1, and 24.1 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 18.0,19.3, 21.2, 21.5, and 24.9 degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.2, 17.0, 18.0, 18.6, 19.3, 21.2, 21.5, 22.1, 24.1, and 24.9 degrees 20 (± 0.2 degrees 20).

[0272] In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 10. In some embodiments,mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 10.

[0273] In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 10.

[0274] In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 10. In someembodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 10.

[0275] In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 10. In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 10.

[0276] In some embodiments, mesylate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 30.

[0277] In some embodiments, mesylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 222 °C. In some embodiments, mesylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 218°C and an endothermic peak at about 222°C.

[0278] In some embodiments, mesylate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 31.

[0279] In some embodiments, mesylate salt Form I is characterized by 0.5% weight loss upon heating from 125 °C to 225 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, mesylate salt Form I is characterized by about 0.5% weight loss upon heating from about 125 °C to about 225 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, mesylate salt Form I is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, 2%, or 1% by weight upon heating from about 125 °C to about 225 °C, as measured by a thermal gravimetric analysis (TGA).

[0280] In some embodiments, mesylate salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 31.

[0281] In some embodiments, mesylate salt Form I is characterized by a weight gain of about 19% after undergoing a dynamic vapor sorption profile cycle from about 0% relative humidity (RH) to about 90% RH at 25 °C.

[0282] In some embodiments, mesylate salt Form I is characterized by a dynamic vapor sorption (DVS) profile substantially as shown in FIG. 32.

[0283] In some embodiments, mesylate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 33.

[0284] In some embodiments, mesylate salt Form I is substantially free of other crystalline or amorphous forms. ix. Mesylate salt of Compound 1 (Form II)

[0285] In some aspects, the crystalline form is a mesylate salt of Compound 1. In some embodiments, the crystalline form is mesylate salt Form II. In some embodiments, mesylate salt Form II is an anhydrate.

[0286] In one embodiment, the present disclosure provides mesylate salt Form II of Compound 1. In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.7, 15.4, 17.2, 17.6, and 19.1 degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 10.0, 10.3, 11.4, 15.0, and 16.5degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 12.1,20.2, 22.7, 23.2, and 24.1 degrees 20 (± 0.2 degrees 20).

[0287] In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.7, 15.4, 17.5, 19.1, and 23.2 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 9.9,10.3, 15.0, 17.2, and 20.2 degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.7, 9.9, 10.3, 15.0, 15.4, 17.2, 17.5, 19.1, 20.2, and 23.2 degrees 20 (± 0.2 degrees 20).

[0288] In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 11. In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 11. In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 11. In some embodiments, mesylate salt Form II ischaracterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 11. In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 11.

[0289] In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 11. In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 11. In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 11.

[0290] In some embodiments, mesylate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 34.

[0291] In some embodiments, mesylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 190 °C. In some embodiments, mesylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 176 °C and an endothermic peak at about 190 °C.

[0292] In some embodiments, mesylate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 35.

[0293] In some embodiments, mesylate salt Form II is characterized by 0.2% weight loss upon heating from 140 °C to 205 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, mesylate salt Form II is characterized by about 0.2% weight loss upon heating from about 140 °C to about 205 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, mesylate salt Form II is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, 2%, or 1% by weight upon heating from about 140 °C to about 205 °C, as measured by a thermal gravimetric analysis (TGA).

[0294] In some embodiments, mesylate salt Form II is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 35.

[0295] In some embodiments, mesylate salt Form II is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 36.

[0296] In some embodiments, mesylate salt Form II is substantially free of other crystalline or amorphous forms. x. Mesylate salt of Compound 1 (Form III)

[0297] In some aspects, the crystalline form is a mesylate salt of Compound 1. In some embodiments, the crystalline form is mesylate salt Form III. In some embodiments, mesylate salt Form III is a solvate or anhydrate.

[0298] In one embodiment, the present disclosure provides mesylate salt Form III of Compound 1. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.5, 8.9, 17.5, 18.5, and 19.6 degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form III is characterized by an XRPD pattern further comprising one or more peaks selected from 6.1, 13.1, 13.8, 14.4, and 19.4 degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form III is characterized by an XRPD pattern further comprising one or more peaks selected from 13.3, 18.0, 21.4, 23.6, and 26.0 degrees 20 (± 0.2 degrees 20).

[0299] In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.5, 8.9, 18.5, 19.6, and 21.4 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 6.1, 13.8, 17.5, 19.4, and 23.6 degrees 20 (± 0.2 degrees 20). In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.1, 6.5, 8.9, 13.8, 17.5, 18.5, 19.4, 19.6, 21.4, and 23.6 degrees 20 (± 0.2 degrees 20).

[0300] In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 12.

[0301] In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of atleast 15% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 12.

[0302] In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 12. In some embodiments, mesylate saltForm III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 12.

[0303] In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 12. In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 12.

[0304] In some embodiments, mesylate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FTG. 37.

[0305] In some embodiments, mesylate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 173 °C. In some embodiments, mesylate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 138 °C and an endothermic peak at about 173 °C.

[0306] In some embodiments, mesylate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 38.

[0307] In some embodiments, mesylate salt Form III is characterized by 1.5% weight loss upon heating from 80 °C to 180 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, mesylate salt Form III is characterized by about 1.5% weight loss upon heating from about 80 °C to about 180 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, mesylate salt Form III is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, or 2% by weight upon heating from about 80 °C to about 180 °C, as measured by a thermal gravimetric analysis (TGA).

[0308] In some embodiments, mesylate salt Form III is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 38.

[0309] In some embodiments, mesylate salt Form III is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 39.

[0310] In some embodiments, mesylate salt Form III is substantially free of other crystalline or amorphous forms. xi. Maleate salt of Compound 1 (Form I)

[0311] In some aspects, the crystalline form is a maleate salt of Compound 1. In some embodiments, the crystalline form is maleate salt Form I. In some embodiments, maleate salt Form I is an anhydrate.

[0312] In one embodiment, the present disclosure provides maleate salt Form I of Compound 1. In some embodiments, maleate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.7, 14.8, 15.5, 18.7, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, maleate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 7.9, 8.3, 9.9, 12.7, and 18.1degrees 20 (± 0.2 degrees 20). In some embodiments, maleate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 16.7, 21.2, 22.5,23.3, and 24.0 degrees 20 (± 0.2 degrees 20).

[0313] In some embodiments, maleate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.8, 15.5, 18.7, 22.5, and 23.3 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 7.9,8.3, 8.7, 9.9, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, maleate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 7.9, 8.3, 8.7, 9.9, 14.8, 15.5, 18.7, 20.0, 22.5, and 23.3 degrees 20 (± 0.2 degrees 20).

[0314] In some embodiments, maleate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 13. In some embodiments, maleate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 13. In some embodiments, maleate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 13. In some embodiments, maleate salt Form I ischaracterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 13. In some embodiments, maleate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 13.

[0315] In some embodiments, maleate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 40.

[0316] In some embodiments, maleate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 195°C. In some embodiments, maleate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 191 °C and an endothermic peak at about 195°C.

[0317] In some embodiments, maleate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 41.

[0318] In some embodiments, maleate salt Form I is characterized by no weight loss prior to decomposition, as measured by a thermal gravimetric analysis (TGA). In some embodiments, maleate salt Form I is characterized by no substantial weight loss prior to decomposition, as measured by a thermal gravimetric analysis (TGA). In some embodiments, maleate salt Form I is characterized by a weight loss of no greater than 5%, 4%, 3%, 2%, 1%, or 0.5% by weight upon heating prior to decomposition, as measured by a thermal gravimetric analysis (TGA).

[0319] In some embodiments, maleate salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 41.

[0320] In some embodiments, maleate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 42.

[0321] In some embodiments, maleate salt Form I is substantially free of other crystalline or amorphous forms. xii. Maleate salt of Compound 1 (Form II)

[0322] In some aspects, the crystalline form is a maleate salt of Compound 1. In some embodiments, the crystalline form is maleate salt Form II. In some embodiments, maleate salt Form II is an acetone solvate.

[0323] In one embodiment, the present disclosure provides maleate salt Form II of Compound 1. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.3, 15.3, 17.5, 18.3, and 18.8 degrees 20 (± 0.2 degrees 20). In some embodiments, maleate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 9.6, 11.9, 13.3,14.2, and 19.3 degrees 20 (± 0.2 degrees 20). In some embodiments, maleate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 17.9, 21.4, 24.0, 24.3, and 24.7 degrees 20 (± 0.2 degrees 20).

[0324] In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.3, 15.3, 17.5, 18.3, and 24.0 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 11.9,13.3, 14.2, 18.8, and 21.4 degrees 20 (± 0.2 degrees 20). In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.9, 13.3, 14.2, 14.3, 15.3, 17.5, 18.3, 18.8, 21.4, and 24.0 degrees 20 (± 0.2 degrees 20).

[0325] In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 14.

[0326] In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed inTable 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 14.

[0327] In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 14.

[0328] In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 30% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 30% as listed in Table 14. In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 30% as listed in Table 14.

[0329] In some embodiments, maleate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 43.

[0330] In some embodiments, maleate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic peak at about 142 °C and / or a second endothermic peak at about 162 °C. In some embodiments, maleate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic onset and peak temperature of about 135 °C and 142 °C, respectively, and / or a second endothermic onset and endothermic peak at about 155 °C and 162 °C, respectively. In some embodiments, maleate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic onset and peak temperature of about 135 °C and about 142 °C, respectively, and / or a second endothermic onset and endothermic peak at about 155 °C and about 162 °C, respectively.

[0331] In some embodiments, maleate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 44.

[0332] In some embodiments, maleate salt Form II is characterized by 1.6% weight loss upon heating from 80 °C to 144 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, maleate salt Form II is characterized by about 1.6% weight loss upon heating from about 80 °C to about 144 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, maleate salt Form II is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, or 2% by weight upon heating from about 80 °C to about 144 °C, as measured by a thermal gravimetric analysis (TGA).

[0333] In some embodiments, maleate salt Form II is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 44.

[0334] In some embodiments, maleate salt Form II is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 45.

[0335] In some embodiments, maleate salt Form II is substantially free of other crystalline or amorphous forms. xiii. Citrate salt of Compound 1 (Form I)

[0336] In some aspects, the crystalline form is a citrate salt of Compound 1. In some embodiments, the crystalline form is citrate salt Form I. In some embodiments, citrate salt Form I is an acetone solvate or anhydrate.

[0337] In one embodiment, the present disclosure provides citrate salt Form I of Compound 1. In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.4, 15.8, 17.9, 19.2, and 19.5 degrees 20 (± 0.2 degrees 20). In some embodiments, citrate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 10.6, 13.1, 15.1, 17.0, and 18.9 degrees 20 (± 0.2 degrees 20). In some embodiments, citrate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 20.3, 22.6, 23.1, 24.5, and 27.1 degrees 20 (± 0.2 degrees 20).

[0338] In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.4, 15.8, 19.2, 20.3, and 27.1 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 17.9,19.5, 22.6, 23.1, and 24.5 degrees 20 (± 0.2 degrees 20). In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.4, 15.8, 17.9, 19.2, 19.5, 20.3, 22.6, 23.1, 24.5, and 27.1 degrees 20 (± 0.2 degrees 20).

[0339] In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 15. In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 15. In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 15. In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 15. In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 15.

[0340] In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 15. In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 15.

[0341] In some embodiments, citrate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 46.

[0342] In some embodiments, citrate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 167 °C. In some embodiments, citrate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 159 °C and an endothermic peak at about 167 °C.

[0343] In some embodiments, citrate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 47.

[0344] In some embodiments, citrate salt Form I is characterized by 22% weight loss upon heating from 95 °C to 225 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, citrate salt Form I is characterized by about 22% weight loss upon heating from about 95 °C to about 225 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, citrate salt Form I is characterized by a weight loss of no greater thanabout 30%, 25%, or 22% by weight upon heating from about 95 °C to about 225 °C, as measured by a thermal gravimetric analysis (TGA).

[0345] In some embodiments, citrate salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 47.

[0346] In some embodiments, citrate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 48.

[0347] In some embodiments, citrate salt Form I is substantially free of other crystalline or amorphous forms. xiv. Fumarate salt of Compound 1 (Form I)

[0348] In some aspects, the crystalline form is a fumarate salt of Compound 1. In some embodiments, the crystalline form is fumarate salt Form I. In some embodiments, fumarate salt Form I is a THF solvate.

[0349] In one embodiment, the present disclosure provides fumarate salt Form I of Compound 1. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.2, 8.5, 10.6, 18.8, and 19.8 degrees 20 (± 0.2 degrees 20). In some embodiments, fumarate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 12.7, 13.0, 15.9, 17.0, and 19.4 degrees 20 (± 0.2 degrees 20). In some embodiments, fumarate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 21.1, 21.4, 23.4, 25.7, and 27.4 degrees 20 (± 0.2 degrees 20).

[0350] In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.2, 10.6, 19.8, 21.4, and 23.4 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 8.5, 17.0, 18.8, 19.4, and 25.7 degrees 20 (± 0.2 degrees 20). In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.2, 8.5, 10.6, 17.0, 18.8, 19.4, 19.8, 21.4, 23.4, and 25.7 degrees 20 (± 0.2 degrees 20).

[0351] In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 16. In some embodiments,fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 16.

[0352] In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 16.

[0353] In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 16. In someembodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 16.

[0354] In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 16. In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 16.

[0355] In some embodiments, fumarate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 49.

[0356] In some embodiments, fumarate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 198°C. In some embodiments, fumarate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 194°C and an endothermic peak at about 198 °C.

[0357] In some embodiments, fumarate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 50.

[0358] In some embodiments, fumarate salt Form I is characterized by 9.7% weight loss upon heating from 100 °C to 210 °C, as measured by a thermal gravimetric analysis (TGA).In some embodiments, fumarate salt Form I is characterized by about 9.7% weight loss upon heating from about 100 °C to about 210 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, fumarate salt Form I is characterized by a weight loss of no greater than about 20%, 15%, or 10% by weight upon heating from about 100 °C to about 210 °C, as measured by a thermal gravimetric analysis (TGA).

[0359] In some embodiments, fumarate salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 50.

[0360] In some embodiments, fumarate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 51.

[0361] In some embodiments, fumarate salt Form I is substantially free of other crystalline or amorphous forms. xv. Fumarate salt of Compound 1 (Form II)

[0362] In some aspects, the crystalline form is a fumarate salt of Compound 1. In some embodiments, the crystalline form is fumarate salt Form II. In some embodiments, fumarate salt Form II is an acetone solvate.

[0363] In one embodiment, the present disclosure provides fumarate salt Form II of Compound 1. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.2, 8.5, 10.5, 12.9, and 18.9 degrees 29 (± 0.2 degrees 20). In some embodiments, fumarate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 15.1, 16.0, 18.6, 19.6, and 20.0 degrees 20 (± 0.2 degrees 20). In some embodiments, fumarate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 21.7, 23.3, 23.6, 26.1, and 27.7 degrees 20 (± 0.2 degrees 20).

[0364] In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.2, 8.5, 12.9, 21.7, and 23.6 degrees 20 (± 0.2 degrees 20). In some embodiments the XRPD pattern further comprises peaks at 10.5, 16.0, 18.9, 20.0, and 26.1 degrees 20 (± 0.2 degrees 20). In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.2, 8.5, 10.5, 12.9, 16.0, 18.9, 20.0, 21.7, 23.6, and 26.1 degrees 20 (± 0.2 degrees 20).

[0365] In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 17.

[0366] In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 17.

[0367] In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 17. In some embodiments, fumarate salt Form II is characterizedby an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 17.

[0368] In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 17. In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 17.

[0369] In some embodiments, fumarate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 52.

[0370] In some embodiments, fumarate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic peak at about 144 °C and / or a second endothermic peak at about 200 °C. In some embodiments, fumarate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic onset and peak at about 144 °C, and / or a second endothermic onset and peak at about 197 °C and 200 °C, respectively.

[0371] In some embodiments, fumarate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 53.

[0372] In some embodiments, fumarate salt Form II is characterized by 2.1% weight loss upon heating from 90 °C to 175 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, fumarate salt Form II is characterized by about 2.1% weight loss upon heating from about 90 °C to about 175 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, fumarate salt Form II is characterized by a weight loss of no greater than about 10%, 5%, 4%, or 3% by weight upon heating from about 90 °C to about 175 °C, as measured by a thermal gravimetric analysis (TGA).

[0373] In some embodiments, fumarate salt Form II is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 53.

[0374] In some embodiments, fumarate salt Form II is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 54.

[0375] In some embodiments, fumarate salt Form II is substantially free of other crystalline or amorphous forms. xvi. Fumarate salt of Compound 1 (Form III)

[0376] In some aspects, the crystalline form is a fumarate salt of Compound 1. In some embodiments, the crystalline form is fumarate salt Form III. In some embodiments, fumarate salt Form III is an ethyl acetate solvate.

[0377] In one embodiment, the present disclosure provides fumarate salt Form III of Compound 1. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.7, 7.9, 8.9, 10.6, and 17.4 degrees20 (± 0.2 degrees 20). In some embodiments, fumarate salt Form III is characterized by an XRPD pattern further comprising one or more peaks selected from 10.3, 11.5, 16.1, 17.9, and 18.5 degrees 20 (± 0.2 degrees 20). In some embodiments, fumarate salt Form III is characterized by an XRPD pattern further comprising one or more peaks selected from 2.1,21.9, 24.0, 25.1, and 26.9 degrees 20 (± 0.2 degrees 20).

[0378] In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.7, 7.9, 8.9, 10.6, and 17.4 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 11.5, 16.1,17.9, 18.5, and 25.1 degrees 20 (± 0.2 degrees 20). In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.7, 7.9, 8.9, 10.6, 11.5, 16.1, 17.4, 17.9, 18.5, and 25.1 degrees 20 (± 0.2 degrees 20).

[0379] In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 18.

[0380] In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized byan X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 18.

[0381] In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 18.

[0382] In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 18. In some embodiments, fumarate salt Form III is characterizedby an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 30% as listed in Table 18. In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 30% as listed in Table 18.

[0383] In some embodiments, fumarate salt Form III is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 55.

[0384] In some embodiments, fumarate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic peak at about 113 °C and / or a second endothermic peak at about 164 °C. In some embodiments, fumarate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic onset and peak at about 106 °C and 113 °C, respectively, and / or a second endothermic onset and peak at about 158 °C and 164 °C, respectively.

[0385] In some embodiments, fumarate salt Form III is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 56.

[0386] In some embodiments, fumarate salt Form III is characterized by 3.1% weight loss upon heating from 85 °C to 135 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, fumarate salt Form III is characterized by about 3.1% weight loss upon heating from about 85 °C to about 135 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, fumarate salt Form III is characterized by a weight loss of nogreater than about 10%, 5%, or 4% by weight upon heating from about 85 °C to about 135 °C, as measured by a thermal gravimetric analysis (TGA).

[0387] In some embodiments, fumarate salt Form III is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 56.

[0388] In some embodiments, fumarate salt Form III is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 57.

[0389] In some embodiments, fumarate salt Form III is substantially free of other crystalline or amorphous forms. xvii. Malate salt of Compound 1 (Form I)

[0390] In some aspects, the crystalline form is a malate salt of Compound 1. In some embodiments, the crystalline form is malate salt Form I. In some embodiments, malate salt Form I is acetone solvate.

[0391] In one embodiment, the present disclosure provides malate salt Form I of Compound 1. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 10.9, 12.4, 13.9, 18.7, and 19.4 degrees 20 (± 0.2 degrees 20). In some embodiments, malate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 4.1, 8.3, 10.5, 16.0, and 16.3 degrees 20 (± 0.2 degrees 20). In some embodiments, malate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 20.0, 20.5, 21.1, 22.9, and 24.7 degrees 20 (± 0.2 degrees 20).

[0392] In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 10.9, 12.4, 19.4, 20.0, and 20.5 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 10.5,13.9, 21.1, 22.9, and 24.7 degrees 20 (± 0.2 degrees 20). In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at10.5. 10.9. 12.4. 13.9, 19.4, 20.0, 20.5, 21.1, 22.9, and 24.7 degrees 20 (± 0.2 degrees 20).

[0393] In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 19. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 19. In some embodiments,malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 19. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 19. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 19.

[0394] In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 19. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 19. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 19. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 19.

[0395] In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 19. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 19. In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 19.

[0396] In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 19.

[0397] In some embodiments, malate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 58.

[0398] In some embodiments, malate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic peak at about 157 °C, and / or a second endothermic peak at about 206 °C. In some embodiments, malate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic onset and peak at about 147 °C and 157 °C, respectively, and / or a second endothermic onset and peak at about 181 °C and 206 °C, respectively. In some embodiments,malate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including a first endothermic onset and peak at about 147 °C and about 157 °C, respectively, and / or a second endothermic onset and peak at about 181 °C and about 206 °C, respectively.

[0399] In some embodiments, malate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 59.

[0400] In some embodiments, malate salt Form I is characterized by 1.9% weight loss upon heating from 75 °C to 157 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, malate salt Form I is characterized by about 1.9% weight loss upon heating from about 75 °C to about 157 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, malate salt Form I is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, or 2% by weight upon heating from about 75 °C to about 157 °C, as measured by a thermal gravimetric analysis (TGA).

[0401] In some embodiments, malate salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 59.

[0402] In some embodiments, malate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 60.

[0403] In some embodiments, malate salt Form I is substantially free of other crystalline or amorphous forms. xviii. Malate salt of Compound 1 (Form II)

[0404] In some aspects, the crystalline form is a malate salt of Compound 1. In some embodiments, the crystalline form is malate salt Form II. In some embodiments, malate salt Form II is an anhydrate.

[0405] In one embodiment, the present disclosure provides malate salt Form II of Compound 1. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.2, 12.4, 14.7, 15.8, and 18.3 degrees 20 (± 0.2 degrees 20). In some embodiments, malate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 4.0, 15.6, 16.4, 17.0, and 19.1 degrees 20 (± 0.2 degrees 20). In some embodiments, malate salt Form II is characterized by an XRPD pattern further comprising one or more peaks selected from 21.5, 22.2, 22.9, 24.4, and 26.2 degrees 20 (± 0.2 degrees 20).

[0406] In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.2, 14.7, 15.8, 18.3, and 24.4 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 12.4, 19.1, 21.5, 22.9, and 26.2 degrees 20 (± 0.2 degrees 20). In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.2, 12.4, 14.7, 15.8, 18.3, 19.1, 21.5, 22.9, 24.4, and 26.2 degrees 20 (± 0.2 degrees 20).

[0407] In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in able 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 20.

[0408] In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 20. In some embodiments, malatesalt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 20.

[0409] In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 20.

[0410] In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed inTable 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 30% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 30% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 30% as listed in Table 20. In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 30% as listed in Table 20.

[0411] In some embodiments, malate salt Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 61.

[0412] In some embodiments, malate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 183 °C. In some embodiments, malate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 180 °C and an endothermic peak at about 183 °C.

[0413] In some embodiments, malate salt Form II is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 62.

[0414] In some embodiments, malate salt Form II is characterized by 0.5% weight loss upon heating from about 95 °C to about 170 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, malate salt Form II is characterized by about 0.5% weight loss upon heating from about 95 °C to about 170 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, malate salt Form II is characterized by a weight loss of no greater than about 10%, 5%, 4%, 3%, 2%, or 1% by weight upon heating from about 95 °C to about 170 °C, as measured by a thermal gravimetric analysis (TGA).

[0415] In some embodiments, malate salt Form II is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 62.

[0416] In some embodiments, malate salt Form II is characterized by a weight gain of about 1.8% after undergoing a dynamic vapor sorption profile cycle from about 0% relative humidity (RH) to about 90% RH at 25 °C.

[0417] In some embodiments, malate salt Form II is characterized by a dynamic vapor sorption (DVS) profile substantially as shown in FIG. 63.

[0418] In some embodiments, malate salt Form II is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 64.

[0419] In some embodiments, malate salt Form II is substantially free of other crystalline or amorphous forms. xix. Succinate salt of Compound 1 (Form I)

[0420] In some aspects, the crystalline form is a succinate salt of Compound 1. In some embodiments, the crystalline form is succinate salt Form I. In some embodiments, succinate salt Form I is an acetone solvate.

[0421] In one embodiment, the present disclosure provides succinate salt Form I of Compound 1. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 10.5, 12.8, 15.0, 18.8, and 19.9 degrees 20 (± 0.2 degrees 20). In some embodiments, succinate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 8.5, 10.7, 12.1, 15.9, and 18.5 degrees 20 (± 0.2 degrees 20). In some embodiments, succinate salt Form I is characterized by an XRPD pattern further comprising one or more peaks selected from 21.4,22.8, 23.3, 24.5, and 24.8 degrees 20 (± 0.2 degrees 20).

[0422] In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.8, 15.0, 18.8, 21.4, and 24.8 degrees 20 (± 0.2 degrees 20). In some embodiments, the XRPD pattern further comprises peaks at 10.5,19.9, 22.8, 23.3, and 24.5 degrees 20 (± 0.2 degrees 20). In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 10.5, 12.8, 15.0, 18.8, 19.9, 21.4, 22.8, 23.3, 24.5, and 24.8 degrees 20 (± 0.2 degrees 20).

[0423] In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three, four, five, or seven, ten, or more peaks listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks listed in Table 21. In some embodiments, succinate salt Form I ischaracterized by an X-ray powder diffraction (XRPD) pattern comprising seven peaks listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising ten peaks listed in Table 21.

[0424] In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 15% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 15% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 15% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 15% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 15% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 15% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 15% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 15% as listed in Table 21.

[0425] In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 20% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 20% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 20% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed inTable 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 20% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least seven peaks having a relative intensity of at least 20% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least eight peaks having a relative intensity of at least 20% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least nine peaks having a relative intensity of at least 20% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least ten peaks having a relative intensity of at least 20% as listed in Table 21.

[0426] In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least two peaks having a relative intensity of at least 30% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three peaks having a relative intensity of at least 30% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least four peaks having a relative intensity of at least 30% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 21. In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least six peaks having a relative intensity of at least 30% as listed in Table 21.

[0427] In some embodiments, succinate salt Form I is characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 65.

[0428] In some embodiments, succinate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endothermic peak at about 136 °C. In some embodiments, succinate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram including an onset temperature of about 128 °C and an endothermic peak at about 136 °C.

[0429] In some embodiments, succinate salt Form I is characterized by a differential scanning calorimetry (DSC) thermogram substantially in accordance with FIG. 66.

[0430] In some embodiments, succinate salt Form I is characterized by 2.8% weight loss upon heating from 85 °C to 145 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, succinate salt Form I is characterized by about 2.8% weight loss upon heating from about 85 °C to about 145 °C, as measured by a thermal gravimetric analysis (TGA). In some embodiments, succinate salt Form I is characterized by a weight loss of no greater than about 10%, 5%, 4%, or 3% by weight upon heating from about 85 °C to about 145 °C, as measured by a thermal gravimetric analysis (TGA).

[0431] In some embodiments, succinate salt Form I is characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 66.

[0432] In some embodiments, succinate salt Form I is characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 67.

[0433] In some embodiments, succinate salt Form I is substantially free of other crystalline or amorphous forms.C. Solid State Forms

[0434] Provided herein are various solid state forms of Compound 1, comprising at least 50 wt% of a particular crystalline form as described herein. In some embodiments, the solid state form comprises at least 60 wt% of a particular crystalline form as described herein. In some embodiments, the solid state form comprises at least 70 wt% of a particular crystalline form as described herein. In some embodiments, the solid state form comprises at least 80 wt% of a particular crystalline form as described herein. In some embodiments, the solid state form comprises at least 90 wt% of a particular crystalline form as described herein. In some embodiments, the solid state form comprises at least 95 wt% of a particular crystalline form as described herein. In some embodiments, the solid state form comprises at least 99 wt% of a particular crystalline form as described herein. In some embodiments, the particular crystalline form is HC1 salt Form I. In some embodiments, the particular crystalline form is free base Form I. In some embodiments, the particular crystalline form is free base Form II.D. Pharmaceutical Compositions

[0435] Provided herein are pharmaceutical compositions comprising a crystalline form of Compound 1 described herein or pharmaceutical compositions prepared using a crystalline form of Compound 1 described herein. Also provided are pharmaceutical compositions comprising a solid state form as described herein, or a pharmaceutical compositions prepared using a solid state form described herein. Pharmaceutical compositions will include one or more pharmaceutically acceptable excipients. In some embodiments, provided herein are pharmaceutical compositions comprising a crystalline form of Compound 1 described herein and one or more pharmaceutically acceptable excipients. In some embodiments, provided herein are pharmaceutical compositions prepared using a crystalline form of Compound 1 described herein and one or more pharmaceutically acceptable excipients. In some embodiments, provided herein are pharmaceutical compositions comprising a solid state form described herein and one or more pharmaceutically acceptable excipients. In some embodiments, provided herein are pharmaceutical compositions prepared using a solid state form described herein and one or more pharmaceutically acceptable excipients.

[0436] The pharmaceutical compositions provided herein may be used in the methods disclosed herein; thus, for example, the pharmaceutical compositions can be administered ex vivo or in vivo to a subject in order to practice the therapeutic methods and uses described herein.

[0437] Pharmaceutical compositions may be in the form suitable for administration to a patient. The pharmaceutical compositions can be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein. Furthermore, the pharmaceutical compositions may be used in combination with other therapeutically active agents or compounds as described herein in order to treat the diseases, disorders and conditions contemplated by the present disclosure.

[0438] The compositions may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).

[0439] The compositions may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and / or preservative agents. Tablets, capsules and the like contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets, capsules, and the like. These excipients may be, for example, diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.

[0440] The tablets, capsules and the like suitable for oral administration may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action. For example, a time-delay material such as glyceryl monostearate or glyceryl di-stearate may be employed. The tablets may also be coated by techniques known in the art to form osmotic therapeutic tablets for controlled release. Additional agents include biodegradable or biocompatible particles or a polymeric substance such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, polyanhydrides, polyglycolic acid, ethylene-vinyl acetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide and glycolide copolymers, polylactide and glycolide copolymers, or ethylene vinyl acetate copolymers in order to control delivery of an administered composition. For example, the oral agent can be entrapped in microcapsules prepared by coacervation techniques or by interfacial polymerization, by the use of hydroxymethyl cellulose or gelatin-microcapsules or poly (methyl methacrylate) microcapsules, respectively, or in a colloid drug delivery system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, microbeads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Methods for the preparation of the above-mentioned formulations are known in the art.

[0441] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, kaolin or microcrystalline cellulose, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

[0442] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture thereof. Such excipients can be suspending agents, for example sodium carboxymethylcellulose, methylcellulose, (hydroxypropyl)methyl cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example a naturally-occurring phosphatide (e.g., lecithin), or condensation products of an alkylene oxide with fatty acids (e.g., poly-oxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols (e.g., for heptdecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol (e.g., polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives.

[0443] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.

[0444] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified herein.

[0445] The pharmaceutical compositions may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin, or mixtures of these. Suitable emulsifying agents may be naturally occurring gums, for example, gum acacia or gum tragacanth; naturally occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids; hexitol anhydrides, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.

[0446] Liquid compositions for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing) are also contemplated. Suitable pharmaceutically acceptable excipients include, but are not limited to, antioxidants (e.g., ascorbic acid andsodium bisulfate), preservatives (e.g., benzyl alcohol, methyl parabens, ethyl or n-propyl, p- hydroxybenzoate), emulsifying agents, suspending agents, dispersing agents, solvents, fillers, bulking agents, detergents, buffers, vehicles, diluents, and / or adjuvants. For example, a suitable vehicle may be physiological saline solution or citrate buffered saline, possibly supplemented with other materials common in pharmaceutical compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Those skilled in the art will readily recognize a variety of buffers that can be used in the pharmaceutical compositions and dosage forms contemplated herein.Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. As an example, the buffer components can be water soluble materials such as phosphoric acid, tartaric acids, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and salts thereof. Acceptable buffering agents include, for example, a Tris buffer, N-(2-Hydroxyethyl)piperazine-N'-(2- ethanesulfonic acid) (HEPES), 2-(N-Morpholino)ethanesulfonic acid (MES), 2-(N- Morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-Morpholino)propanesulfonic acid (MOPS), and N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS).

[0447] After a pharmaceutical composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form, a lyophilized form requiring reconstitution prior to use, a liquid form requiring dilution prior to use, or other acceptable form. In some embodiments, the pharmaceutical composition is provided in a single-use container (e.g., a single-use vial, ampoule, syringe, or autoinjector (similar to, e.g., an EpiPen®)), whereas a multi-use container (e.g., a multi-use vial) is provided in other embodiments.

[0448] Formulations can also include carriers to protect the composition against rapid degradation or elimination from the body, such as a controlled release formulation, including liposomes, hydrogels, prodrugs and microencapsulated delivery systems. For example, a time delay material such as glyceryl monostearate or glyceryl stearate alone, or in combination with a wax, may be employed. Any drug delivery apparatus may be used to deliver a composition described herein, including implants (e.g., implantable pumps) and catheter systems, slow injection pumps and devices, all of which are well known to the skilled artisan.

[0449] An effective amount of a crystalline form of Compound 1 described herein for use in therapy is an amount of Compound 1 sufficient to treat or prevent a proliferative condition referred to herein, slow its progression and / or reduce the symptoms associated with the condition.

[0450] An effective amount of a pharmaceutical composition described herein (i.e., a pharmaceutical composition comprising a crystalline form of Compound 1 described herein, a pharmaceutical composition prepared using a crystalline form of Compound 1 described herein, a pharmaceutical composition comprising a solid state form as described herein, or a pharmaceutical composition prepared using a solid state form described herein), for use in therapy is an amount of Compound 1 sufficient to treat or prevent a proliferative condition referred to herein, slow its progression and / or reduce the symptoms associated with the condition.

[0451] The size of the dose for therapeutic or prophylactic purposes of a crystalline form of Compound 1 described herein will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine. The size of the dose for therapeutic or prophylactic purposes of a pharmaceutical composition described herein will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.

[0452] In using a crystalline form of Compound 1 described herein for therapeutic or prophylactic purposes it will generally be administered so that a total daily dose of Compound 1 in the range, for example, 0.01 mg / kg to 100 mg / kg body weight is received. In using a pharmaceutical composition described herein for therapeutic or prophylactic purposes it will generally be administered so that a total daily dose of Compound 1 in the range, for example, 0.01 mg / kg to 100 mg / kg body weight is received. Oral administration may also be suitable, particularly in tablet form.E. Methods of Treatment

[0453] Provided herein are crystalline forms of compounds that function as inhibitors of PARG.

[0454] The present invention therefore provides a method of inhibiting PARG enzyme activity in vitro or in vivo, said method comprising contacting a cell with an effective amountof a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein.

[0455] The present invention also provides a method of treating a disease or disorder in which PARG activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein. In an embodiment, the disease or disorder is an advanced or metastatic solid tumor. In an embodiment, the disease or disorder is cancer. In an embodiment, the cancer is ovarian, gastric, or breast cancer. In an embodiment, the cancer is lung, cervical, or pancreatic cancer. In an embodiment, the cancer is non-small cell lung cancer (NSCLC). In an embodiment, the cancer is prostate cancer. In an embodiment, the cancer is triple negative breast cancer (TNBC). In an embodiment, the cancer is a homologous recombinant deficient (HRD) cancer.

[0456] Provided herein is a method of inhibiting cell proliferation, in vitro or in vivo, said method comprising contacting a cell with an effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein.

[0457] Provided herein is a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein. In an embodiment, the proliferative disorder is a solid tumor. In an embodiment, the proliferative disorder is a metastatic solid tumor. In an embodiment, the proliferative disorder is cancer. In an embodiment, the cancer is ovarian, gastric, or breast cancer. In an embodiment, the cancer is lung, cervical or pancreatic cancer. In an embodiment, the cancer is prostate cancer. In an embodiment, the cancer is prostate cancer, colorectal cancer, or endometrial cancer. In an embodiment, the cancer is colorectal cancer. In an embodiment, the cancer is prostate cancer. In an embodiment, the cancer is endometrial cancer. In an embodiment, the cancer is ovarian cancer, gastric cancer, breast cancer, lung cancer, cervical cancer, pancreatic cancer, prostate cancer, colorectal cancer, or endometrial cancer. In an embodiment, the cancer is a homologous recombinant deficient (HRD) cancer.

[0458] Provided herein is a method of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein. In an embodiment, the cancer is ovarian, gastric, or breast cancer. In an embodiment, the cancer is lung, cervical or pancreatic cancer. In an embodiment, the cancer is a homologous recombinant deficient (HRD) cancer.

[0459] Provided herein is a method of treating and / or preventing a homologous recombinant deficient (HRD) cancer in a patient comprising administering to the patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein. In an embodiment, the patient is in recognized need of such treatment. In an embodiment, the homologous recombinant deficient (HRD) cancer is breast cancer, ovarian cancer, gastric cancer, prostate cancer, lung cancer, cervical cancer, or pancreatic cancer. In an embodiment, the homologous recombinant deficient (HRD) cancer is breast cancer, ovarian cancer, gastric cancer, lung cancer, cervical cancer, pancreatic cancer, prostate cancer, colorectal cancer, or endometrial cancer.

[0460] In some embodiments, provided are methods of treating and / or preventing a cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, thereby treating the cancer in the subject, wherein the cancer is a homologous recombinant deficient (HRD) cancer, and the cancer is Estrogen Receptor (ER) positive. In an embodiment, the cancer is breast cancer or ovarian cancer.

[0461] In some embodiments, provided are methods of treating and / or preventing a cancer in a subject in need thereof, the methods comprising administering to the subject a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, thereby treating the cancer in the subject, wherein the cancer is an HRD cancer, the cancer is ER positive, and the cancer is optionally Progesterone Receptor (PR) positive. In some embodiments, provided are methods of treating and / or preventing a cancer in a subject in need thereof, the methods comprising administering to the subject a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, thereby treating the cancer in the subject, wherein the cancer is an HRDcancer, the cancer is ER positive, and the cancer is PR positive. In an embodiment, the cancer is breast cancer or ovarian cancer.

[0462] In some embodiments, provided are methods of treating and / or preventing a cancer in a subject in need thereof, the methods comprising administering to the subject a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, thereby treating the cancer in the subject, wherein the cancer is an HRD cancer, the cancer is ER positive, and the cancer is optionally human epidermal growth factor receptor 2 (HER2) negative. In some embodiments, provided are methods of treating and / or preventing a cancer in a subject in need thereof, the methods comprising administering to the subject a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, thereby treating the cancer in the subject, wherein the cancer is HRD cancer, the cancer is ER positive, and the cancer is HER2 negative. In an embodiment, the cancer is breast or ovarian cancer.

[0463] In some embodiments, provided are methods of treating and / or preventing a cancer in a subject in need thereof, the methods comprising administering to the subject a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, thereby treating the cancer in the subject, wherein the cancer is an HRD cancer, the cancer is ER positive, the caner is optionally PR positive, and the cancer is optionally HER2 negative. In an embodiment, the cancer is breast or ovarian cancer.

[0464] In some embodiments, provided are methods of treating and / or preventing a breast cancer in a subject in need thereof, the methods comprising administering to the subject a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, thereby treating the cancer in the subject, wherein the cancer is an HRD cancer, the cancer is ER positive, the cancer is optionally PR positive, and the cancer is optionally HER2 negative.

[0465] Provided herein is a method of treating and / or preventing a cancer in a patient, where the cancer is characterized by a reduction or absence of BRCA1 and / or BRCA2 gene expression, an absence or mutation of BRCA1 and / or BRCA2 genes, or a reduced function of BRCA1 and / or BRCA2 proteins, comprising administering to the patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein. In an embodiment, the cancer is ovarian,gastric, or breast cancer. In an embodiment, the cancer is lung, cervical or pancreatic cancer. In an embodiment, the cancer is prostate cancer.

[0466] In an embodiment, the cancer is PARP inhibitor-resistant. In some embodiments, the PARP inhibitor-resistant cancer is resistant to any one or more of niraparib, olaparib, rucaparib, talazoparib, veliparib, AZD5305, and AZD9574. In some embodiments, the PARP inhibitor-resistant cancer is resistant to niraparib. In some embodiments the PARP inhibitor-resistant cancer is resistant to olaparib. In some embodiments, the PARP inhibitorresistant cancer is ovarian cancer, breast cancer, or pancreatic cancer.

[0467] In an embodiment, the cancer is platin-resistant. In some embodiments, the platin- resistant cancer is resistant to any one or more of cisplatin, carboplatin, satraplatin, heptaplatin, picoplatin, nedaplatin, triplatin, lipoplatin, and oxaliplatin. In some embodiments, the platin-resistant cancer is resistant to cisplatin. In some embodiments, the platin-resistant cancer is resistant to carboplatin.

[0468] Provided herein are methods of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, wherein the patient has been determined to be resistant to one or more PARP inhibitors. In some embodiments, said methods comprise administering to said patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, wherein said patient has been diagnosed as resistant to one or more PARP inhibitors.

[0469] Provided herein are methods of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, wherein the patient has been determined to be resistant to platinum based chemotherapeutics. In some embodiments, said methods comprise administering to said patient a therapeutically effective amount of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, wherein said patient has been diagnosed as resistant to one or more platinum based chemotherapeutics.

[0470] Provided herein is a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein for use in therapy.

[0471] Provided herein is a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein for use in the treatment of a proliferative condition.

[0472] Provided herein is a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein for use in the treatment of cancer. In a particular embodiment, the cancer is human cancer. In an embodiment, the cancer is ovarian, gastric, or breast cancer. In an embodiment, the cancer is lung, cervical or pancreatic cancer. In an embodiment, the cancer is prostate cancer. In an embodiment, the cancer is a homologous recombinant deficient (HRD) cancer.

[0473] Provided herein is a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein for use in the inhibition of PARG enzyme activity.

[0474] Provided herein is a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein for use in the treatment of a disease or disorder in which PARG activity is implicated.

[0475] Provided herein is a use of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein in the manufacture of a medicament for the treatment of a proliferative condition.

[0476] Provided herein is a use of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein in the manufacture of a medicament for the treatment of cancer. Suitably, the medicament is for use in the treatment of human cancers. In an embodiment, the cancer is ovarian, gastric, or breast cancer. In an embodiment, the cancer is lung, cervical or pancreatic cancer. In an embodiment, the cancer is prostate cancer. In an embodiment, the cancer is a homologous recombinant deficient (HRD) cancer.

[0477] Provided herein is a use of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein in the manufacture of a medicament for the inhibition of PARG enzyme activity.

[0478] Provided herein is a use of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein in the manufacture of a medicament for the treatment of a disease or disorder in which PARG activity is implicated.

[0479] The present disclosure also contemplates the use of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein in combination with other therapeutically active agents or compounds as described herein in order to treat the diseases, disorders and conditions contemplated by the present disclosure. In some embodiments, the additional therapeutic agent is a chemotherapeutic agent. In some embodiments, the additional therapeutic agent is a MAT2A inhibitor. In some embodiments, the additional therapeutic agent is a PRMT5 inhibitor. In some embodiments, the PRMT5 inhibitor is a MTA-cooperative PRMT5 inhibitor. In some embodiments, the additional therapeutic agent is a cell cycle checkpoint inhibitor. In some embodiments, the additional therapeutic agent is immunecheckpoint inhibitor.

[0480] The term “proliferative disorder” and “proliferative condition” are used interchangeably herein and pertain to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo. Examples of proliferative conditions include, but are not limited to, pre-malignant and malignant cellular proliferation, including but not limited to, malignant neoplasms and tumors, cancers, leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g., of connective tissues), and atherosclerosis. Any type of cell may be treated, including but not limited to, lung, colon, breast, ovarian, prostate, gastric, liver, pancreas, brain, and skin. Proliferative disorders also include, for example, advanced or metastatic solid tumors.

[0481] The anti-proliferative effects of a crystalline form of Compound 1 described herein, or a pharmaceutical composition thereof as defined and described herein, have particular application in the treatment of human cancers (by virtue of their inhibition of PARG enzyme activity).

[0482] The anti-cancer effect may arise through one or more mechanisms, including but not limited to, the regulation of cell proliferation, the inhibition of angiogenesis (the formation of new blood vessels), the inhibition of metastasis (the spread of a tumor from its origin), the inhibition of invasion (the spread of tumor cells into neighboring normal structures), or the promotion of apoptosis (programmed cell death).

[0483] In a particular embodiment of the disclosure, the proliferative condition to be treated is cancer.F. Methods of Preparation

[0484] Compound 1 can be prepared, for example, as described in Example 1.

[0485] The various salt forms described herein can be prepared, for example, as described in the provided Examples. It is understood that there may be more than one crystallization method that will yield the described free base, HC1, sulfate, tosylate, besylate, mesylate, maleate, citrate, fumarate, malate, and succinate forms.

[0486] In one aspect, the present disclosure provides a method for preparing a crystalline form of Compound 1. In one aspect, the present disclosure provides a method for preparing a crystalline salt form of Compound 1. In some embodiments, the method includes:1) forming a first mixture comprising Compound 1 and a first solvent;2) adding an acid to the first mixture to form a second mixture;3) optionally adding a second solvent to the second mixture;4) stirring the second mixture;5) isolating the precipitate; and6) drying the precipitate to provide the crystalline form of the salt of Compound 1.

[0487] In some embodiments, the method for preparing a crystalline form of Compound 1 includes:1) forming a first mixture comprising Compound 1 and a first solvent;2) adding an acid to the first mixture to form a second mixture;3) optionally adding a second solvent to the second mixture to form a third mixture;4) stirring the second mixture when steps 1) and 2) are conducted, or stirring the third mixture when steps 1) to 3) are conducted;5) isolating the precipitate; and6) drying the precipitate to provide the crystalline form of the salt of Compound 1.

[0488] In another aspect, the present disclosure provides a method for preparing a crystalline free base form of Compound 1. In some embodiments, the method includes:1) forming a first mixture comprising Compound 1 and a first solvent;2) optionally adding a second solvent to the first mixture;3) stirring the first mixture;4) isolating the precipitate; and5) drying the precipitate to provide the crystalline form of Compound 1.

[0489] In some embodiments, the method for preparing a crystalline free base form of Compound 1 includes:1) forming a first mixture comprising Compound 1 and a first solvent;2) optionally adding a second solvent to the first mixture to form a second mixture;3) stirring the first mixture when step 1) is conducted, or stirring the second mixture when steps 1) and 2) are condcted;4) isolating the precipitate; and5) drying the precipitate to provide the crystalline form of Compound 1.

[0490] In some embodiments, all steps as described above are performed at room temperature. In some embodiments, all steps as described above are conducted at 10 °C to 40 °C.

[0491] In some embodiments, the first mixture is formed at room temperature. In some embodiments, the first mixture is heated to a temperature of between about 40 °C and about 70 °C. In some embodiments, the first mixture is heated to a temperature of about 50 °C. In some embodiments, the first mixture is heated to a temperature of about 60 °C.

[0492] In some embodiments, the first solvent is selected from the group consisting of acetone, acetonitrile, ethyl acetate, methanol, ethanol, isopropanol, and tetrahydrofuran. In some embodiments, the first solvent is selected from the group consisting of acetone, acetonitrile, ethyl acetate, methanol, ethanol, isopropanol, NMP (N-methyl pyrrolidone), DMSO (dimethylsulfoxide), and tetrahydrofuran.

[0493] In some embodiments, the acid is selected from the group consisting of HC1, sulfuric acid, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, maleic acid, citric acid, fumaric acid, L-malic acid, and succinic acid.

[0494] In some embodiments, the second solvent is selected from the group consisting of heptane, methyl tert-butyl ether (MTBE), and water. In some embodiments, the second solvent is selected from the group consisting of hexane, heptane, methyl tert-butyl ether (MTBE), and water.

[0495] In some embodiments, provided is a method of preparing HC1 salt Form I of Compound 1. In some embodiments, the method includes 1) forming a first mixture comprising Compound 1 and methanol, and heating the first mixture to a temperature of about 50 °C, 2) adding HC1 to form a second mixture, 3) adding MTBE to the second mixture, 4) stirring the second mixture at room temperature, 5) isolating the solids, and 6) drying the solids. In some embodiments, the method includes 1) forming a first mixture comprising Compound 1 and methanol, and heating the first mixture to a temperature of about 50 °C, 2) adding HC1 to form a second mixture, 3) adding MTBE to the second mixture to form a third mixture, 4) stirring the third mixture at room temperature, 5) isolating the solids, and 6) drying the solids. In some embodiments, the solids are dried under vacuum. In some embodiments, the solids are dried at elevated temperature. In some embodiments, the solids are dried under vacuum at a temperature of about at 50 °C.

[0496] In some embodiments, provided is a method of preparing free base Form I of Compound 1. In some embodiments, the method includes 1) forming a first mixture comprising Compound 1 and an alcohol solvent, 3) stirring the first mixture, 4) isolating the precipitate, and 5) drying the precipitate. In some embodiments, the alcohol solvent is methanol or ethanol. In some embodiments, the method includes slurrying Compound 1 in methanol or ethanol at elevated temperature. In some embodiments, the method includes slurrying Compound 1 in methanol or ethanol at about 50 °C. In some embodiments, the method includes slurrying Compound 1 in ethanol at about 50 °C. In some embodiments, the method includes isolating the solids, e.g. by filtration. In some embodiments, the solids are dried under vacuum. In some embodiments, the solids are dried at elevated temperature. In some embodiments, the solids are dried under vacuum at a temperature of about at 50 °C.

[0497] In some embodiments, provided is a method of preparing free base Form II of Compound 1. In some embodiments, the method includes 1) forming a first mixturecomprising Compound 1 and DMSO, 2) adding water to the first mixture, 3) stirring the first mixture, 4) isolating the precipitate, and 5) drying the precipitate. In some embodiments, the method includes 1) forming a first mixture comprising Compound 1 and DMSO, 2) adding water to the first mixture to form a second mixture, 3) stirring the second mixture, 4) isolating the precipitate, and 5) drying the precipitate. In some embodiments, the method includes isolating the solids, e.g. by filtration. In some embodiments, the solids are dried under vacuum. In some embodiments, the solids are dried at elevated temperature. In some embodiments, the solids are dried under vacuum at a temperature of about at 50 °C.G. Non-limiting Exemplary Embodiments

[0498] Embodiment 1. A crystalline form of Compound 1(Compound 1), or a salt thereof.

[0499] Embodiment 2. The crystalline form of embodiment 1, wherein the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

[0500] Embodiment s. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is HC1 salt Form I.

[0501] Embodiment 4. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 13.2 and 17.7 degrees 20 (± 0.2 degrees 20).

[0502] Embodiment 5. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks selected from 11.7, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 19.9.

[0503] Embodiment 6. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising four peaks selected from 11.7,13.2. 13.7. 15.3. 17.2, 17.7, 18.4, and 19.9.

[0504] Embodiment 7. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks selected from 11.7,13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 19.9.

[0505] Embodiment 8. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 13.2, 13.7, and 17.7 degrees 20 (± 0.2 degrees 20).

[0506] Embodiment 9. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.7, 13.2, 13.7, and 17.7 degrees 20 (± 0.2 degrees 20).

[0507] Embodiment 12. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.7, 13.2, 13.7, 17.7, and 18.4 degrees 20 (± 0.2 degrees 20).

[0508] Embodiment 11. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.7, 13.2, 13.7, 17.2, 17.7, and 18.4 degrees 20 (± 0.2 degrees 20).

[0509] Embodiment 12. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.7, 13.2, 13.7, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20).

[0510] Embodiment 13. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.7, 13.2, 13.7, 15.3,17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20).

[0511] Embodiment 14. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 7.0, 11.7, 13.2, 13.7,15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20).

[0512] Embodiment 15. The HC1 salt Form I, according to embodiment 3, characterized by an XRPD pattern comprising peaks at 7.0, 11.7, 12.2, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20).

[0513] Embodiment 16. The HC1 salt Form I, according to any one of embodiments 8 to 15, characterized by an XRPD pattern further comprising one or more peaks selected from 20.9, 24.3, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

[0514] Embodiment 17. The HC1 salt Form I, according to any one of embodiments 8 to 15, characterized by an XRPD pattern further comprising one or more peaks selected from 20.6, 20.9, 21.2, 21.7, 22.3, 24.3, 25.0, 25.3, 25.6, 26.1, 28.9 degrees 20 (± 0.2 degrees 20).

[0515] Embodiment 18. The HC1 salt Form I, according to any one of embodiments 8 to 15, characterized by an XRPD pattern further comprising a peak at 28.9 degrees 20 (± 0.2 degrees 20).

[0516] Embodiment 19. The HC1 salt Form I, according to any one of embodiments 8 to 15, characterized by an XRPD pattern further comprising peaks at 26.1 and 28.9 degrees 20 (± 0.2 degrees 20).

[0517] Embodiment 20. The HC1 salt Form I, according to any one of embodiments 8 to 15, characterized by an XRPD pattern further comprising peaks at 24.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

[0518] Embodiment 21. The HC1 salt Form I, according to any one of embodiments 8 to 15, characterized by an XRPD pattern further comprising peaks at 20.9, 24.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

[0519] Embodiment 22. The HC1 salt Form I, according to any one of embodiments 8 to 15, characterized by an XRPD pattern further comprising peaks at 20.9, 24.3, 25.3, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

[0520] Embodiment 23. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 3.

[0521] Embodiment 24. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 20% as listed in Table 3.

[0522] Embodiment 25. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 30% as listed in Table 3.

[0523] Embodiment 26. The HC1 salt Form I, according to embodiment 3, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 7.

[0524] Embodiment 27. The HC1 salt Form I, according to any one of embodiments 3 to 26, characterized by a differential scanning calorimetry thermogram (DSC) comprising no endotherm prior to decomposition.

[0525] Embodiment 28. The HC1 salt Form I, according to any one of embodiments 3 to 26, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 8.

[0526] Embodiment 29. The HC1 salt Form I, according to any one of embodiments 3 to 28, characterized by no weight loss upon heating prior to decomposition, as measured by thermal gravimetric analysis (TGA).

[0527] Embodiment 30. The HC1 salt Form I, according to any one of embodiments 3 to 28, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 8.

[0528] Embodiment 31. The HC1 salt Form I, according to any one of embodiments 3 to30, characterized by a weight gain of about 0.5 % after undergoing a dynamic vapor sorption cycle from about 0% relative humidity (RH) to about 90% RH at 25 °C.

[0529] Embodiment 32. The HC1 salt Form I, according to any one of embodiments 3 to31, characterized by a dynamic vapor sorption profile substantially as shown in FIG. 9.

[0530] Embodiment 33. The HC1 salt Form I, according to any one of embodiments 3 to32, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 10.

[0531] Embodiment 34. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is free base Form I.

[0532] Embodiment 35. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0 and 18.3 degrees 20 (± 0.2 degrees 20).

[0533] Embodiment 36. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising three peaks selected from 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

[0534] Embodiment 37. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising four peaks selected from 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

[0535] Embodiment 38. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising five peaks selected from 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

[0536] Embodiment 39. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 16.4, and 18.3 degrees 20 (± 0.2 degrees 20).

[0537] Embodiment 40. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 16.4, 18.0, and 18.3 degrees 20 (± 0.2 degrees 20).

[0538] Embodiment 41. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 16.4, 18.0, 18.3, and 19.4 degrees 20 (± 0.2 degrees 20).

[0539] Embodiment 42. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 12.7, 16.4, 18.0, 18.3, and 19.4 degrees 20 (± 0.2 degrees 20).

[0540] Embodiment 43. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 12.7, 16.4, 18.0, 18.3, 18.9, and 19.4 degrees 20 (± 0.2 degrees 20).

[0541] Embodiment 44. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, and 19.4 degrees 20 (± 0.2 degrees 20).

[0542] Embodiment 45. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

[0543] Embodiment 46. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 11.5, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

[0544] Embodiment 47. The free base Form I of any one of embodiments 39 to 46, characterized by an XRPD pattern further comprising one or more peaks selected from 22.5, 23.2, 23.5, 24.6, and 27.8 degrees 26 (± 0.2 degrees 26).

[0545] Embodiment 48. The free base Form I of any one of embodiments 39 to 46, characterized by an XRPD pattern further comprising one or more peaks selected from 23.2, 23.5, and 24.6 degrees 26 (± 0.2 degrees 20).

[0546] Embodiment 49. The free base Form I of embodiment 34, characterized by an X- ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 1.

[0547] Embodiment 50. The free base Form I, according to any one of embodiments 34 to 49, characterized by a differential scanning calorimetry thermogram (DSC) comprising a melting point peak at about 200 °C.

[0548] Embodiment 51. The free base Form I, according to any one of embodiments 34 to 49, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 2.

[0549] Embodiment 52. The free base Form I, according to any one of embodiments 34 to 51, characterized by no weight loss upon heating prior to decomposition, as measured by thermal gravimetric analysis (TGA).

[0550] Embodiment 53. The free base Form I, according to any one of embodiments 34 to 51, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 2.

[0551] Embodiment 54. The free base Form I, according to any one of embodiments 34 to 53, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 3.

[0552] Embodiment 55. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is free base Form II.

[0553] Embodiment 56. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3 and 18.7 degrees 26 (± 0.2 degrees 26).

[0554] Embodiment 57. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising three peaks selected from 12.3, 15.6,17.1, 18.7, 19.5, and 19.7 degrees 26 (± 0.2 degrees 26).

[0555] Embodiment 58. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising four peaks selected from 12.3, 15.6, 17.1, 18.7, 19.5, and 19.7 degrees 26 (± 0.2 degrees 20).

[0556] Embodiment 59. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising five peaks selected from 12.3, 15.6,17.1. 18.7. 19.5, and 19.7 degrees 20 (± 0.2 degrees 20).

[0557] Embodiment 60. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, and 18.7 degrees 20 (± 0.2 degrees 20).

[0558] Embodiment 61. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks atl2.3, 15.6, 17.1, and 18.7 degrees 20 (± 0.2 degrees 20).

[0559] Embodiment 62. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, 17.1, 18.7, and 19.5 degrees 26 (± 0.2 degrees 26).

[0560] Embodiment 63. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, 17.1, 18.7, 19.5, and 19.7 degrees 20 (± 0.2 degrees 26).

[0561] Embodiment 64. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 15.6, 16.4, 17.1, 18.7,19.5, and 19.7 degrees 20 (± 0.2 degrees 26).

[0562] Embodiment 65. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 13.4, 15.6, 16.4, 17.1, 18.7, 19.5, and 19.7 degrees 26 (± 0.2 degrees 20).

[0563] Embodiment 66. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 13.4, 15.6, 16.1, 16.4, 17.1, 18.7, 19.5, and 19.7 degrees 26 (± 0.2 degrees 20).

[0564] Embodiment 67. The free base Form II of embodiment 55, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.3, 13.4, 14.1, 15.6, 16.1, 16.4, 17.1, 18.7, 19.5, and 19.7 degrees 26 (± 0.2 degrees 20).

[0565] Embodiment 68. The free base Form II of any one of embodiments 60 to 67, characterized by an XRPD pattern further comprising one or more peaks selected from 20.2, 20.7, 23.0, 25.0, 25.7, 26.5, and 31.4 degrees 20 (± 0.2 degrees 20).

[0566] Embodiment 69. The free base Form II of any one of embodiments 60 to 67, characterized by an XRPD pattern further comprising one or more peaks selected from 20.2, 20.7, 23.0, 25.7, and 26.5 degrees 20 (± 0.2 degrees 20).

[0567] Embodiment 70. The free base Form I of embodiment 55, characterized by an X- ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 4.

[0568] Embodiment 71. The free base Form II, according to any one of embodiments 55 to 70, characterized by a differential scanning calorimetry thermogram (DSC) comprising a first endotherm peak at about 148 °C and / or a second endotherm peak at about 198 °C.

[0569] Embodiment 72. The free base Form II, according to any one of embodiments 55 to 70, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 5.

[0570] Embodiment 73. The free base Form II, according to any one of embodiments 55 to 72, characterized by a 15.1% weight loss upon heating to about 158 °C, as measured by thermal gravimetric analysis (TGA).

[0571] Embodiment 74. The free base Form II, according to any one of embodiments 55 to 72, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 5.

[0572] Embodiment 75. The free base Form II, according to any one of embodiments 55 to 74, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 6.

[0573] Embodiment 76. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is sulfate salt Form I.

[0574] Embodiment 77. The sulfate salt Form I of embodiment 76, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.0, 8.5, 13.2, 15.6, and 16.1 degrees 20 (± 0.2 degrees 20).

[0575] Embodiment 78. The sulfate salt Form I of embodiment 77, characterized by an XRPD pattern further comprising one or more peaks selected from 8.8, 12.9, 15.0, 17.2, and 19.0 degrees 20 (± 0.2 degrees 20).

[0576] Embodiment 79. The sulfate salt Form I of embodiment 77 or 78, characterized by an XRPD pattern further comprising one or more peaks selected from 20.2, 22.1, 24.3, 25.1, and 26.7 degrees 20 (± 0.2 degrees 20).

[0577] Embodiment 80. The sulfate salt Form I of embodiment 76, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 11.

[0578] Embodiment 81. The sulfate salt Form I, according to any one of embodiments 76 to 80, characterized by a differential scanning calorimetry thermogram (DSC) comprising a first endotherm peak at about 118 °C, a second endotherm peak at about 220 °C, an exotherm peak at about 231 °C, and / or a third endotherm peak at about 279 °C.

[0579] Embodiment 82. The sulfate salt Form I, according to any one of embodiments 76 to 80, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 12.

[0580] Embodiment 83. The sulfate salt Form I, according to any one of embodiments 76 to 82, characterized by about 2.8% weight loss upon heating to around 130 °C, as measured by thermal gravimetric analysis (TGA).

[0581] Embodiment 84. The sulfate salt Form I, according to any one of embodiments 76 to 82, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 12.

[0582] Embodiment 85. The sulfate salt Form I, according to any one of embodiments 76 to 84, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 13.

[0583] Embodiment 86. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is tosylate salt Form I.

[0584] Embodiment 87. The tosylate salt Form I of embodiment 86, characterized by anX-ray powder diffraction (XRPD) pattern comprising peaks at 6.8, 9.6, 14.5, 18.2, and 19.5 degrees 20 (± 0.2 degrees 20).

[0585] Embodiment 88. The tosylate salt Form I of embodiment 87, characterized by an XRPD pattern further comprising one or more peaks selected from 4.7, 11.7, 13.7, 15.5, and 15.9 degrees 20 (± 0.2 degrees 20).

[0586] Embodiment 89. The tosylate salt Form I of embodiment 87 or 88, characterized by an XRPD pattern further comprising one or more peaks selected from 21.4, 22.8, 24.0, 24.3, and 29.3 degrees 20 (± 0.2 degrees 20).

[0587] Embodiment 90. The tosylate salt Form I of embodiment 86, characterized by anX-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 14.

[0588] Embodiment 91. The tosylate salt Form I, according to any one of embodiments 86 to 90, characterized by a differential scanning calorimetry thermogram (DSC) comprising a melthing point peak at about 231 °C.

[0589] Embodiment 92. The tosylate salt Form I, according to any one of embodiments 86 to 90, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 15.

[0590] Embodiment 93. The tosylate salt Form I, according to any one of embodiments 86 to 92, characterized by about 1.2% weight loss upon heating from about 110 °C to about 230 °C, as measured by thermal gravimetric analysis (TGA).

[0591] Embodiment 94. The tosylate salt Form I, according to any one of embodiments 86 to 92, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 15.

[0592] Embodiment 95. The tosylate salt Form I, according to any one of embodiments 86 to 94, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 16.

[0593] Embodiment 96. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is tosylate salt Form II.

[0594] Embodiment 97. The tosylate salt Form II of embodiment 96, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.7, 14.3, 15.4, 17.3, and 19.1 degrees 20 (± 0.2 degrees 20).

[0595] Embodiment 98. The tosylate salt Form II of embodiment 97, characterized by an XRPD pattern further comprising one or more peaks selected from 9.1, 10.2, 13.0, 17.0, and 18.4 degrees 20 (± 0.2 degrees 20).

[0596] Embodiment 99. The tosylate salt Form II of embodiment 97 or 98, characterized by an XRPD pattern further comprising one or more peaks selected from 20.1, 20.5, 23.8, 24.2, and 26.2 degrees 20 (± 0.2 degrees 20).

[0597] Embodiment 100. The tosylate salt Form II of embodiment 96, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 17.

[0598] Embodiment 101. The tosylate salt Form II, according to any one of embodiments 96 to 100, characterized by a differential scanning calorimetry thermogram (DSC) comprising a melting point peak at about 229 °C.

[0599] Embodiment 102. The tosylate salt Form II, according to any one of embodiments 96 to 100, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 18.

[0600] Embodiment 103. The tosylate salt Form II, according to any one of embodiments 96 to 102, characterized by about 1.4% weight loss upon heating from about 90 °C to about 230 °C, as measured by thermal gravimetric analysis (TGA).

[0601] Embodiment 104. The tosylate salt Form II, according to any one of embodiments 96 to 102, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 18.

[0602] Embodiment 105. The tosylate salt Form II, according to any one of embodiments 96 to 104, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 19.

[0603] Embodiment 106. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is tosylate salt Form III.I l l

[0604] Embodiment 107. The tosylate salt Form III of embodiment 106, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.9, 14.5, 15.5, 18.2, and 19.5 degrees 20 (± 0.2 degrees 20).

[0605] Embodiment 108. The tosylate salt Form III of embodiment 107, characterized by an XRPD pattern further comprising one or more peaks selected from 9.7, 14.1, 14.9, 16.0, and 16.9 degrees 20 (± 0.2 degrees 20).

[0606] Embodiment 109. The tosylate salt Form III of embodiment 107 or 108, characterized by an XRPD pattern further comprising one or more peaks selected from 21.2, 21.4, 22.0, 24.0, and 24.4 degrees 20 (± 0.2 degrees 20).

[0607] Embodiment 110. The tosylate salt Form III of embodiment 106, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 20.

[0608] Embodiment 111. The tosylate salt Form III, according to any one of embodiments 106 to 110, characterized by a differential scanning calorimetry thermogram (DSC) comprising a melting point peak at 222 °C.

[0609] Embodiment 112. The tosylate salt Form III, according to any one of embodiments 106 to 110, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 21.

[0610] Embodiment 113. The tosylate salt Form III, according to any one of embodiments 106 to 112, characterized by about 2.6% weight loss upon heating from about 110 °C to about 222 °C, as measured by thermal gravimetric analysis (TGA).

[0611] Embodiment 114. The tosylate salt Form III, according to any one of embodiments 106 to 112, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 21.

[0612] Embodiment 115. The tosylate salt Form III, according to any one of embodiments 106 to 114, characterized by a weight gain of about 3.2% after undergoing a dynamic vapor sorption cycle from about 0 % relative humidity (RH) to about 90 % RH at 25 °C.

[0613] Embodiment 116. The tosylate salt Form III, according to any one of embodiments 106 to 114, characterized by a dynamic vapor sorption profile substantially as shown in FIG. 22.

[0614] Embodiment 117. The tosylate salt Form III, according to any one of embodiments 106 to 116, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 23.

[0615] Embodiment 118. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is besylate salt Form I.

[0616] Embodiment 119. The besylate salt Form I of embodiment 118, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.8, 14.5, 15.4, 17.3, and 19.1 degrees 20 (± 0.2 degrees 20).

[0617] Embodiment 120. The besylate salt Form I of embodiment 119, characterized by an XRPD pattern further comprising one or more peaks selected from 15.0, 15.9, 17.7, 18.3, and 19.6 degrees 20 (± 0.2 degrees 20).

[0618] Embodiment 121. The besylate salt Form I of embodiment 119 or 120, characterized by an XRPD pattern further comprising one or more peaks selected from 20.3, 20.8, 24.0, 25.2, and 26.0 degrees 20 (± 0.2 degrees 20).

[0619] Embodiment 122. The besylate salt Form I of embodiment 118, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 24.

[0620] Embodiment 123. The besylate salt Form I, according to any one of embodiments 119 to 122, characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at about 202 °C.

[0621] Embodiment 124. The besylate salt Form I, according to any one of embodiments 118 to 122, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 25.

[0622] Embodiment 125. The besylate salt Form I, according to any one of embodiments 118 to 124, characterized by about 0.6% weight loss upon heating from about 100 °C to about 210 °C, as measured by thermal gravimetric analysis (TGA).

[0623] Embodiment 126. The besylate salt Form I, according to any one of embodiments 118 to 124, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 25.

[0624] Embodiment 127. The besylate salt Form I, according to any one of embodiments 118 to 126, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 26.

[0625] Embodiment 128. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is besylate salt Form II.

[0626] Embodiment 129. The besylate salt Form II of embodiment 128, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 7.6, 15.2, 15.7, 19.2, and 19.7 degrees 20 (± 0.2 degrees 20).

[0627] Embodiment 130. The besylate salt Form II of embodiment 129, characterized by an XRPD pattern further comprising one or more peaks selected from 9.0, 10.0, 12.4, 14.7, and 18.1 degrees 20 (± 0.2 degrees 20).

[0628] Embodiment 131. The besylate salt Form II of embodiment 129 or 130, characterized by an XRPD pattern further comprising one or more peaks selected from 10.4, 20.1, 22.9, 25.0, and 26.5 degrees 20 (± 0.2 degrees 20).

[0629] Embodiment 132. The besylate salt Form II of embodiment 128, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 27.

[0630] Embodiment 133. The besylate salt Form II, according to any one of embodiments 128 to 132, characterized by a differential scanning calorimetry thermogram (DSC) comprising an endotherm peak at about 165 °C.

[0631] Embodiment 134. The besylate salt Form II, according to any one of embodiments 128 to 132, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 28.

[0632] Embodiment 135. The besylate salt Form II, according to any one of embodiments 128 to 134, characterized by about 0.5% weight loss upon heating from about 64 °C to about 185 °C, as measured by thermal gravimetric analysis (TGA).

[0633] Embodiment 136. The besylate salt Form II, according to any one of embodiments 128 to 134, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 28.

[0634] Embodiment 137. The besylate salt Form II, according to any one of embodiments 128 to 136, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 29.

[0635] Embodiment 138. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is mesylate salt Form I.

[0636] Embodiment 139. The mesylate salt Form I of embodiment 138, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.2, 17.0, 18.0, 18.6, and 19.3 degrees 20 (± 0.2 degrees 20).

[0637] Embodiment 140. The mesylate salt Form I of embodiment 139, characterized by an XRPD pattern further comprising one or more peaks selected from 11.0, 11.9, 12.7, 15.1, and 17.5 degrees 20 (± 0.2 degrees 20).

[0638] Embodiment 141. The mesylate salt Form I of embodiment 139 or 140, characterized by an XRPD pattern further comprising one or more peaks selected from 20.7, 21.2, 22.1, 24.1, and 25.0 degrees 20 (± 0.2 degrees 20).

[0639] Embodiment 142. The mesylate salt Form I of embodiment 139, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 30.

[0640] Embodiment 143. The mesylate salt Form I, according to any one of embodiments 138 to 142, characterized by a differential scanning calorimetry thermogram (DSC) comprising an endotherm peak at about 222 °C.

[0641] Embodiment 144. The mesylate salt Form I, according to any one of embodiments 138 to 142, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 31.

[0642] Embodiment 145. The mesylate salt Form I, according to any one of embodiments 138 to 144, characterized by about 0.5% weight loss upon heating from about 125 °C to about 225 °C, as measured by thermal gravimetric analysis (TGA).

[0643] Embodiment 146. The mesylate salt Form I, according to any one of embodiments 138 to 144, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 31.

[0644] Embodiment 147. The mesylate salt Form I, according to any one of embodiments 138 to 146, characterized by a weight gain of about 19 % after undergoing a dynamic vapor sorption cycle from about 0 % relative humidity (RH) to about 90 % RH at 25 °C.

[0645] Embodiment 148. The mesylate salt Form I, according to any one of embodiments 138 to 146, characterized by a dynamic vapor sorption profile substantially as shown in FIG.32.

[0646] Embodiment 149. The mesylate salt Form I, according to any one of embodiments 138 to 148, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 33.

[0647] Embodiment 150. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is mesylate salt Form II.

[0648] Embodiment 151. The mesylate salt Form II of embodiment 150, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.7, 15.4, 17.2, 17.6, and 19.1 degrees 20 (± 0.2 degrees 20).

[0649] Embodiment 152. The mesylate salt Form II of embodiment 151, characterized by an XRPD pattern further comprising one or more peaks selected from 10.0, 10.3, 11.4, 15.0, and 16.5 degrees 20 (± 0.2 degrees 20).

[0650] Embodiment 153. The mesylate salt Form II of embodiment 151 or 153, characterized by an XRPD pattern further comprising one or more peaks selected from 12.1, 20.2, 22.7, 23.2, and 24.1 degrees 20 (± 0.2 degrees 20).

[0651] Embodiment 154. The mesylate salt Form II of embodiment 150, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 34.

[0652] Embodiment 155. The mesylate salt Form II, according to any one of embodiments 150 to 154, characterized by a differential scanning calorimetry thermogram (DSC) comprising an endotherm peak at about 190 °C.

[0653] Embodiment 156. The mesylate salt Form II, according to any one of embodiments 150 to 154, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 35.

[0654] Embodiment 157. The mesylate salt Form II, according to any one of embodiments 150 to 156, characterized by about 0.2% weight loss upon heating from about 140 °C to about 205 °C, as measured by thermal gravimetric analysis (TGA).

[0655] Embodiment 158. The mesylate salt Form II, according to any one of embodiments 150 to 156, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 35.

[0656] Embodiment 159. The mesylate salt Form II, according to any one of embodiments 150 to 158, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 36.

[0657] Embodiment 160. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is mesylate salt Form III.

[0658] Embodiment 161. The mesylate salt Form III of embodiment 160, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 6.5, 8.9, 17.5, 18.5, and 19.6 degrees 20 (± 0.2 degrees 20).

[0659] Embodiment 162. The mesylate salt Form III of embodiment 161, characterized by an XRPD pattern further comprising one or more peaks selected from 6.1, 13.1, 13.8, 14.4, and 19.4 degrees 20 (± 0.2 degrees 20).

[0660] Embodiment 163. The mesylate salt Form III embodiment 161 or 162, characterized by an XRPD pattern further comprising one or more peaks selected from 13.3, 18.0, 21.4, 23.6, and 26.0 degrees 20 (± 0.2 degrees 20).

[0661] Embodiment 164. The mesylate salt Form III of embodiment 160, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 37.

[0662] Embodiment 165. The mesylate salt Form III, according to any one of embodiments 160 to 164, characterized by a differential scanning calorimetry thermogram (DSC) comprising a melting peak at about 173 °C.

[0663] Embodiment 166. The mesylate salt Form III, according to any one of embodiments 160 to 164, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 38.

[0664] Embodiment 167. The mesylate salt Form III, according to any one of embodiments 160 to 166, characterized by 1.5% weight loss upon heating from about 80 °C to about 180 °C as measured by thermal gravimetric analysis (TGA).

[0665] Embodiment 168. The mesylate salt Form III, according to any one of embodiments 160 to 166, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 38.

[0666] Embodiment 169. The mesylate salt Form III, according to any one of embodiments 160 to 168, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 39.

[0667] Embodiment 170. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is maleate salt Form I.

[0668] Embodiment 171. The maleate salt Form I of embodiment 170, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 8.7, 14.8, 15.5, 18.7, and 20.0 degrees 20 (± 0.2 degrees 20).

[0669] Embodiment 172. The maleate salt Form I of embodiment 171, characterized by an XRPD pattern further comprising one or more peaks selected from 7.9, 8.3, 9.9, 12.7, and 18.1 degrees 20 (± 0.2 degrees 20).

[0670] Embodiment 173. The maleate salt Form I of embodiment 171 or 172, characterized by an XRPD pattern further comprising one or more peaks selected from 16.7, 21.2, 22.5, 23.3, and 24.0 degrees 20 (± 0.2 degrees 20).

[0671] Embodiment 174. The maleate salt Form I of embodiment 170, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 40.

[0672] Embodiment 175. The maleate salt Form I, according to any one of embodiments 170 to 174, characterized by a differential scanning calorimetry thermogram (DSC) comprising an endotherm peak at about 195 °C.

[0673] Embodiment 176. The maleate salt Form I, according to any one of embodiments 170 to 174, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 41.

[0674] Embodiment 177. The maleate salt Form I, according to any one of embodiments 170 to 176, characterized by no weight loss prior to decomposition, as measured by thermal gravimetric analysis (TGA).

[0675] Embodiment 178. The maleate salt Form I, according to any one of embodiments 170 to 176, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 41.

[0676] Embodiment 179. The maleate salt Form I, according to any one of embodiments 170 to 178, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 42.

[0677] Embodiment 180. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is maleate salt Form II.

[0678] Embodiment 181. The maleate salt Form II of embodiment 180, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 14.3, 15.3, 17.5, 18.3, and 18.8 degrees 20 (± 0.2 degrees 20).

[0679] Embodiment 182. The maleate salt Form II of embodiment 181, characterized by an XRPD pattern further comprising one or more peaks selected from 9.6, 11.9, 13.3, 14.2, and 19.3 degrees 20 (± 0.2 degrees 20).

[0680] Embodiment 183. The maleate salt Form II of embodiment 181 or 182, characterized by an XRPD pattern further comprising one or more peaks selected from 17.9, 21.4, 24.0, 24.3, and 24.7 degrees 20 (± 0.2 degrees 20).

[0681] Embodiment 184. The maleate salt Form II of embodiment 180, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 43.

[0682] Embodiment 185. The maleate salt Form II, according to any one of embodiments 180 to 184, characterized by a differential scanning calorimetry thermogram (DSC) comprising a first endotherm peak at about 142 °C, and / or a second endotherm peak at about 162 °C.

[0683] Embodiment 186. The maleate salt Form II, according to any one of embodiments 180 to 184, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 44.

[0684] Embodiment 187. The maleate salt Form II, according to any one of embodiments 180 to 186, characterized by about 1.6% weight loss upon heating from about 80 °C to about 144 °C, as measured by thermal gravimetric analysis (TGA).

[0685] Embodiment 188. The maleate salt Form II, according to any one of embodiments 180 to 186, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 44.

[0686] Embodiment 189. The maleate salt Form II, according to any one of embodiments 180 to 188, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 45.

[0687] Embodiment 190. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is citrate salt Form I.

[0688] Embodiment 191. The citrate salt Form I of embodiment 190, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 11.4, 15.8, 17.9, 19.2, and 19.5 degrees 20 (± 0.2 degrees 20).

[0689] Embodiment 192. The citrate salt Form I of embodiment 191, characterized by an XRPD pattern further comprising one or more peaks selected from 10.6, 13.1, 15.1, 17.0, and 18.9 degrees 20 (± 0.2 degrees 20).

[0690] Embodiment 193. The citrate salt Form I of embodiment 191 or 192, characterized by an XRPD pattern further comprising one or more peaks selected from 20.3, 22.6, 23.1, 24.5, and 27.1 degrees 20 (± 0.2 degrees 20).

[0691] Embodiment 194. The citrate salt Form I of embodiment 190, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 46.

[0692] Embodiment 195. The citrate salt Form I, according to any one of embodiments 190 to 194, characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at about 167 °C.

[0693] Embodiment 196. The citrate salt Form I, according to any one of embodiments 190 to 194, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 47.

[0694] Embodiment 197. The citrate salt Form I, according to any one of embodiments 190 to 196, characterized by about 22% weight loss upon heating from about 95 °C to about 225 °C, as measured by thermal gravimetric analysis (TGA).

[0695] Embodiment 198. The citrate salt Form I, according to any one of embodiments 190 to 196, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 47.

[0696] Embodiment 199. The citrate salt Form I, according to any one of embodiments 190 to 198, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 48.

[0697] Embodiment 200. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is fumarate salt Form I.

[0698] Embodiment 201. The fumarate salt Form I of embodiment 200, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.2, 8.5, 10.6, 18.8, and 19.8 degrees 20 (± 0.2 degrees 20).

[0699] Embodiment 202. The fumarate salt Form I of embodiment 201, characterized by an XRPD pattern further comprising one or more peaks selected from 12.7, 13.0, 15.9, 17.0, and 19.4 degrees 20 (± 0.2 degrees 20).

[0700] Embodiment 203. The fumarate salt Form I of embodiment 201 or 202, characterized by an XRPD pattern further comprising one or more peaks selected from 21.1, 21.4, 23.4, 25.7, and 27.4 degrees 20 (± 0.2 degrees 20).

[0701] Embodiment 204. The fumarate salt Form I of embodiment 200, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 49.

[0702] Embodiment 205. The fumarate salt Form I, according to any one of embodiments 200 to 205, characterized by a differential scanning calorimetry thermogram (DSC) comprising a melting peak at about 198 °C.

[0703] Embodiment 206. The fumarate salt Form I, according to any one of embodiments 200 to 205, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 50.

[0704] Embodiment 207. The fumarate salt Form I, according to any one of embodiments 200 to 206, characterized by about 9.7% weight loss upon heating from about 100 °C to about 210 °C, as measured by thermal gravimetric analysis (TGA).

[0705] Embodiment 208. The fumarate salt Form I, according to any one of embodiments 200 to 206, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 50.

[0706] Embodiment 209. The fumarate salt Form I, according to any one of embodiments 200 to 208, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 51.

[0707] Embodiment 210. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is fumarate salt Form II.

[0708] Embodiment 211. The fumarate salt Form II of embodiment 210, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 4.2, 8.5, 10.5, 12.9, and 18.9 degrees 20 (± 0.2 degrees 20).

[0709] Embodiment 212. The fumarate salt Form II of embodiment 211, characterized by an XRPD pattern further comprising one or more peaks selected from 15.1, 16.0, 18.6, 19.6, and 20.0 degrees 20 (± 0.2 degrees 20).

[0710] Embodiment 213. The fumarate salt Form II of any one of embodiments 211 or 212, characterized by an XRPD pattern further comprising one or more peaks selected from 21.7, 23.3, 23.6, 26.1, and 27.7 degrees 20 (± 0.2 degrees 20).

[0711] Embodiment 214. The fumarate salt Form II of embodiment 210, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 52.

[0712] Embodiment 215. The fumarate salt Form II, according to any one of embodiments 210 to 214, characterized by a differential scanning calorimetry thermogram (DSC) comprising a first endotherm peak at about 144 °C, and / or a second endotherm peak at about 200 °C.

[0713] Embodiment 216. The fumarate salt Form II, according to any one of embodiments 210 to 214, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 53.

[0714] Embodiment 217. The fumarate salt Form II, according to any one of embodiments 210 to 216, characterized by about 2.1% weight loss upon heating from about 90 °C to about 175 °C, as measured by thermal gravimetric analysis (TGA).

[0715] Embodiment 218. The fumarate salt Form II, according to any one of embodiments 210 to 216, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 53.

[0716] Embodiment 219. The fumarate salt Form II, according to any one of embodiments 210 to 218, characterized by a polarized light microscope (PLM) profile substantially as shown in FIG. 54.

[0717] Embodiment 220. The crystalline form of embodiment 1 or embodiment 2, wherein the crystalline form is fumarate salt Form III.

[0718] Embodiment 221. The fumarate salt Form III of embodiment 220, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.7, 7.9, 8.9, 10.6, and 17.4 degrees 20 (± 0.2 degrees 20).

[0719] Embodiment 222. The fumarate salt Form III of embodiment 221, characterized by XRPD pattern further comprising one or more peaks selected from 10.3, 11.5, 16.1, 17.9, and 18.5 degrees 20 (± 0.2 degrees 20).

[0720] Embodiment 223. The fumarate salt Form III of embodiment 221 or 222, characterized by an XRPD pattern further comprising one or more peaks selected from 2.1, 21.9, 24.0, 25.1, and 26.9 degrees 20 (± 0.2 degrees 20).

[0721] Embodiment 224. The fumarate salt Form III of embodiment 221, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 55.

[0722] Embodiment 225. The fumarate salt Form III, according to any one of embodiments 220 to 224, characterized by a differential scanning calorimetry thermogram (DSC) comprising a first endotherm peak at about 113 °C, and / or a second endotherm peak at about 164 °C.

[0723] Embodiment 226. The fumarate salt Form III, according to any one of embodiments 220 to 224, characterized by a differential scanning calorimetry thermogram (DSC) sub...

Claims

WHAT IS CLAIMED IS:

1. A crystalline form of Compound 1or a salt thereof.

2. The crystalline form of claim 1, wherein the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

3. The crystalline form of claim 1 or claim 2, wherein the crystalline form is HC1 salt Form I.

4. The crystalline form of claim 3, wherein the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

5. The HC1 salt Form I, according to claim 3 or 4, characterized by an X- ray powder diffraction (XRPD) pattern comprising three or more peaks selected from 11 .7, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 19.9 degrees 26 (± 0.2 degrees 26).

6. The HC1 salt Form I, according to claim 3 or 4, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 11.7, 13.2, 13.7, 17.7, and 18.4 degrees 26 (± 0.2 degrees 26).

7. The HC1 salt Form I, according to claim 3 or 4, characterized by an XRPD pattern comprising peaks at 7.0, 11.7, 12.2, 13.2, 13.7, 15.3, 17.2, 17.7, 18.4, and 20.0 degrees 20 (± 0.2 degrees 20).

8. The HC1 salt Form I, according to any one of claims 3 to 7, wherein the XRPD pattern further comprises one or more peaks selected from 20.6, 20.9, 21.2, 21.7, 22.3, 24.3, 25.0, 25.3, 25.6, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

9. The HC1 salt Form I, according to claim 3 or 4, characterized by an X- ray powder diffraction (XRPD) pattern comprising at least five peaks having a relative intensity of at least 15% as listed in Table 3.

10. The HC1 salt Form I, according to claim 3 or 4, characterized by an X- ray powder diffraction (XRPD) pattern comprising peaks at 13.2, 13.7, 17.7, 26.1, and 28.9 degrees 20 (± 0.2 degrees 20).

11. The HC1 salt Form I, according to claim 10, wherein the XRPD pattern further comprises peaks at 20.6, 20.9, 21.2, 24.3, and 25.3 degrees 20 (± 0.2 degrees 20).

12. The HC1 salt Form I, according to claim 3 or 4, characterized by an X- ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 7.

13. The HC1 salt Form I, according to any one of claims 3 to 12, characterized by a differential scanning calorimetry thermogram (DSC) comprising no endotherm prior to decomposition.

14. The HC1 salt Form I, according to any one of claims 3 to 12, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 8.

15. The HC1 salt Form I, according to any one of claims 3 to 14, characterized by no weight loss upon heating prior to decomposition, as measured by thermal gravimetric analysis (TGA).

16. The HC1 salt Form I, according to any one of claims 3 to 14, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 8.

17. The HC1 salt Form I, according to any one of claims 3 to 16, characterized by a weight gain of about 0.5 % after undergoing a dynamic vapor sorption cycle from about 0% relative humidity (RH) to about 90% RH at 25 °C.

18. The HC1 salt Form I, according to any one of claims 3 to 16, characterized by a dynamic vapor sorption profile substantially as shown in FIG. 9.

19. The crystalline form of claim 1 or claim 2, wherein the crystalline form is free base Form I.

20. The crystalline form of claim 19, wherein the crystalline form is a single crystalline form substantially free of other crystalline or amorphous forms.

21. The free base Form I of claim 19 or 20, characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks selected from 9.0, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

22. The free base Form I of claim 19 or 20, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 16.4, 18.0, 18.3, and 19.4 degrees 20 (± 0.2 degrees 20).

23. The free base Form I of claim 19 or 20, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 11.5, 12.7, 13.7, 16.4, 18.0, 18.3, 18.9, 19.4, and 19.7 degrees 20 (± 0.2 degrees 20).

24. The free base Form I of any one of claims 21 to 23, wherein the XRPD pattern further comprises one or more peaks selected from 22.5, 23.2, 23.5, 24.6, and 27.8 degrees 20 (± 0.2 degrees 20).

25. The free base Form I according to claim 19 or 20, characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 9.0, 16.4, 18.3, 23.5, and 24.6 degrees 20 (± 0.2 degrees 20).

26. The free base Form I according to claim 25, wherein the XRPD pattern further comprises peaks at 12.7, 13.7, 18.0, 18.9, and 19.4 degrees 20 (± 0.2 degrees 20).

27. The free base Form I of claim 19 or 20, characterized by an X-ray powder diffraction (XRPD) pattern substantially in accordance with FIG. 1.

28. The free base Form I, according to any one of claims 19 to 27, characterized by a differential scanning calorimetry thermogram (DSC) comprising an endothermic peak at about 200 °C.

29. The free base Form I, according to any one of claims 19 to 27, characterized by a differential scanning calorimetry thermogram (DSC) substantially in accordance with FIG. 2.

30. The free base Form I, according to any one of claims 19 to 29, characterized by no weight loss upon heating prior to decomposition, as measured by thermal gravimetric analysis (TGA).

31. The free base Form I, according to any one of claims 19 to 29, characterized by a thermal gravimetric analysis (TGA) thermogram substantially in accordance with FIG. 2.

32. A pharmaceutical composition comprising a crystalline form according to any one of claims 1 to 31 and at least one pharmaceutically acceptable excipient.

33. A pharmaceutical composition prepared by combining a crystalline form according to any one of claims 1 to 31 and at least one pharmaceutically acceptable excipient.

34. A solid state form of Compound 1 or a salt thereof, wherein the solid state form comprises at least 50 wt.% of a particular crystalline form, at least 60 wt.% of a particular crystalline form, at least 70 wt.% of a particular crystalline form, at least 80 wt.% of a particular crystalline form, at least 90 wt.% of a particular crystalline form, at least 95 wt.% of a particular crystalline form, or at least 99 wt.% of a particular crystalline form, wherein the particular crystalline form is according to any one of claims 1 to 31.

35. The solid state form of claim 34, wherein the particular crystalline form is HC1 salt Form I.

36. The solid state form of claim 34, wherein the particular crystalline form is free base Form I.

37. A pharmaceutical composition comprising a solid state form of any one of claims 34 to 36, and at least one pharmaceutically acceptable excipient.

38. A pharmaceutical composition prepared by combining a solid state form of any one of claims 34 to 36 with at least one pharmaceutically acceptable excipient.

39. A method of treating a cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a crystalline form of any one of claims 1 to 31, or a pharmaceutical composition of any one of claims 32, 33, 37, and 38.

40. A method of treating and / or preventing a homologous recombinant deficient (HRD) cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a crystalline form of any one of claims 1 to 31, or a pharmaceutical composition of any one of claims 32, 33, 37, and 38.

41. A method of treating and / or preventing a cancer in a patient in need thereof, where the cancer is characterized by a reduction or absence of BRCA1 and / or BRCA2 gene expression, the absence or mutation of BRCA1 and / or BRCA2 genes, or reduced function of BRCA1 and / or BRCA2 proteins, the method comprising administering to the patient a therapeutically effective amount of a crystalline form of any one of claims 1 to 31, or a pharmaceutical composition of any one of claims 32, 33, 37, and 38.

42. The crystalline form as defined in any one of claims 1 to 31, or a pharmaceutical composition of any one of claims 32, 33, 37, and 38, for use in the treatment of cancer.

43. Use of a crystalline form as defined in any one of claims 1 to 31, or a pharmaceutical composition of any one of claims 32, 33, 37, and 38, in the manufacture of a medicament for the treatment of cancer.

44. The method of any one of claims 39 to 41, or the use of claim 42 or 43, wherein the cancer is breast cancer, ovarian cancer, gastric cancer, lung cancer, cervical cancer, pancreatic cancer, prostate cancer, colorectal cancer, head and neck cancer, or endometrial cancer.

Images